Healthcare visits of the population 50+ in Europe from 2004 to 2022

Patterns and trends

Van Kinh Nguyen[1,*], Anna Reuter[1,*], Mirna Abd El Aziz[2], and Till Bärnighausen[1]

[1]Heidelberg Institute for Global Health, Heidelberg University, Heidelberg, 69120, Germany
[2]London School of Hygiene and Tropical Medicine, London, UK
[*]Equally contributed

November 12, 2024

Background: The COVID-19 pandemic brought major reductions in healthcare visits in Europe. The long-run consequences for healthcare systems depend on the paths to post-pandemic levels, especially among the groups in highest need of sustained care.

Methods: We used individual longitudinal data from 27 European countries from the Survey of Health, Ageing and Retirement in Europe, divided in three phases: pre-pandemic (2004-2019), pandemic (2021), and post-pandemic (2022). We analysed the number of healthcare visits by gender over time and their correlation with age and chronic conditions using a Bayesian spatio-temporal model.

Results: Before COVID-19, the nominal rate of healthcare visits varied among countries from two to six visits per year and increased over time. The COVID-19 pandemic severely affected the number of healthcare visits, with an estimated reduction from 65% to 95% across countries. During COVID-19, older individuals and those with chronic conditions had a more than proportional reduction in the number of healthcare visits. After COVID-19, the pattern of healthcare visits mostly returned to pre-pandemic levels, with an over-shooting for people with cancer and a lag for people with cardiovascular diseases.

Conclusion: The quick recovery in the number of healthcare visits for most European countries indicate that access to care stabilised again. Yet, the different trends for vulnerable groups show that these groups require timely action to prevent long-term consequences of missed care.

Introduction

The COVID-19 pandemic brought severe disruptions to the healthcare systems worldwide. On the one hand, even relatively resource-rich healthcare systems as in Europe were overwhelmed by the number of intensive care patients and the high infection risk. On the other hand, individuals stayed absent due to fear of infection, mobility restrictions, or rejection by the healthcare providers. In some cases, this might have relieved healthcare systems from overutilization in terms of unnecessary consultations and treatments [1], particularly in systems with a high coverage of health insurance, as in many European countries. Yet, if diagnoses were delayed or chronic care interrupted, the long-run consequences could put an immense burden on the healthcare systems in the near future.

The massive drop in healthcare utilization, especially for outpatient care, during the early phase of the pandemic has been widely documented [2, 3, 4, 5]. While some studies indicate larger reductions among patients in better health [2], others point towards a delay in diagnoses for cardiovascular diseases, diabetes, cancer, and common mental health problems [6, 7, 8]. For delayed melanoma diagnoses alone, it is estimated that $7.65 billion additional costs incurred in Europe [9].

There is few evidence on the trajectory of outpatient care after the initial phase of the pandemic, and most covering periods till 2021 only. In the UK, care for common mental health problems seem to have recovered to pre-pandemic levels by 2021 [10], as did visits to general practitioners and specialists in Germany [11]. In Poland, the number of healthcare users of primary care, specialist care, and preventive programs recovered in 2021, but not the volume of care [12]. In Norway, specialists bookings recovered, but primary care bookings stayed below pre-pandemic levels in 2021 [13]. Similarly, wellness visits and preventive screenings in 2022 remained below pre-pandemic levels in the US [14]. The impact on disparities in access to health is less clear, but among the older population in Europe, those with poorer health were more likely to report missed healthcare visits during the pandemic [15].

We aimed to investigate the trajectories of healthcare visits in Europe before, during and after the pandemic, and shed light on the disparities among the population most in need of sustained healthcare. We focused on the population aged 50 and older, which is particularly in need of regular healthcare based on the high prevalence of chronic conditions and represented in the Survey of Health, Ageing and Retirement in Europe (SHARE). The longitudinal structure allows us to estimate the changes in the number of healthcare visits (NHV) during the pandemic (year 2021) and after the pandemic (years 2021/2022) in comparison to the pre-pandemic period (years 2004-2019), and to analyze the disparities by age, gender, and diagnosed health conditions.

Materials and Methods

Data

Data from 27 European countries were collated from the Survey of Health, Ageing and Retirement in Europe (SHARE), waves 1, 2, 4, 5, 6, 7, 8, 9 [16, 17, 18, 19, 20, 21, 22, 23]

and the second wave of the COVID-19 survey [24]. The SHARE panel includes health and socioeconomic data of respondents aged 50 or older and their partners. The first wave was conducted in 2004, spanning 11 European countries and Israel. The following waves were conducted approximately every two years, and over time further 16 European countries joined SHARE. In March 2020, data collection for wave 8 had to be stopped due to the outbreak of the COVID-19 pandemic. In summer 2020 and summer 2021, two special COVID-19 surveys were conducted over the phone. From October 2021 till December 2022, wave 9 was conducted (with 80% of interviews in 2022), returning back to the standard questionnaire and mode. In the following, we refer to the COVID-19 survey as data from the "pandemic" period, and the wave 9 data as data from the "post-pandemic" period.

The primary outcome was the number of healthcare visits an individual reported in the period prior to the interview (NHV). Healthcare visits were considered as seeing or talking to a medical doctor or qualified nurse, excluding visits to dentists and hospital stays, but including emergency or outpatient clinic visits. In the COVID-19 survey, healthcare visits were recorded as going to a doctor's office or a medical facility other than a hospital. The recall period was 12 months for waves 1-9, and since the last interview/past 12 months for the second COVID-19 survey. For this wave, we used the exact date of interview to calculate the person-month contributed by each individual. For the first COVID-19 survey, the recall period was defined as 'since the COVID-19 outbreak', which might vary based on the respondent's perception on the beginning of the outbreak, and was hence excluded from the analysis. Details can be found in the Appendix S1.

We excluded respondents who were staying at a nursing facility at the time of interview, those younger than 50 years at the time of the interview (these are partners of the main respondents), as they were not considered as target sample, and respondents aged 100 or older to preclude selection effects at high ages. To retain the maximum sample size with an observed number of healthcare visits, we matched individuals across the survey waves and imputed missing values for the covariates (age and gender) by records in the other waves. Existing health conditions were captured as self-reported diagnoses according to a pre-specified list. Health conditions that were collected only in the most recent waves were excluded from the analysis. Ireland participated in only one survey and was not included in this analysis. Overall, data from 147,116 individuals, resulting in 505,607 observations, were included in the analyses.

In addition, we used the following additional country level data to analyse differences across countries: GDP per capita in 2019 [25], government health expenditure as % of GDP in 2019 [26], physician density in 2013 (latest date available) [27], population density in 2019 [27], cumulative deaths by June 2021 [28], and the average stringency index till June 2021 by the Oxford Government Response Tracker [28].

Model and implementation

We implemented a combined likelihoods approach to estimate the covariate effect without the influence of epidemic and post-epidemic data, as well as providing a concrete reference for the estimation of the epidemic effects. First, the number of healthcare visits during a

time period was modelled as a rate per person-month. This allows different periods of recall to be modelled and projected. We constructed a Bayesian hierarchical model for the number of healthcare visit y_{ijt} in the corresponding observation period E_{ijt} months for an individual i in country j at interview time t as follows:

$$y_{ijt} \sim \text{Poisson}(\lambda_{ijt}) \tag{1}$$

$$\lambda_{ijt} = \gamma_{ijt} E_{ijt} \exp(\eta_{ijt}) \tag{2}$$

In particular, we modelled the number of healthcare visits as a Poisson count that was extended to allow a larger variation of the NHV via the over-dispersion parameter (γ) with a unit prior mean, and separately for men and women. For the pre-epidemic data period, the linear predictor is modelled as

$$\eta_{ijt} = \beta_0 + \phi_j + \delta_j t + X_{ijt}\beta_x + f(age_{ijt}) + \epsilon_{ijt} \tag{3}$$

where we assumed a country-specific difference, $\phi_j \sim N(0, \sigma_j^2)$, that varied around the global mean β_0. The mean NHV varied according to a set of health conditions with a shared fixed-effect among the countries, $X_{ijt}\beta_x$. A shared effect of the continuous age variable was modelled with a second-order random walk to allow for potential structured nonlinear effects, denoted by $f(age_{ijt})$. Trends over time, represented by the year of interview, were modelled with a random slope term δ_j, which allows for differences in the trends among the countries. We assumed that the trend among the countries might be correlated and modelled the slopes with the spatially correlated model BYM [29]. Individual identification across the waves was modelled with a normally distributed term $\epsilon_{ijt} \sim N(0, \sigma_e^2)$ to take into account within-individual variability. We used only the data before the COVID-19 pandemic to inform the model's parameters at this step. We tested for beta convergence by regressing the yearly growth rate of the NHV on the initial NHV.

For the epidemic period, the estimated linear predictor from the pre-epidemic model was carried over to provide the reference point for the case without an epidemic. The data of this period provides estimates of the changes compared to what would be predicted given the same individual characteristics. The linear predictor for this period of time u read as

$$\eta_{iju} = \hat{\eta_{ijt}} + X_{iju}\rho_{xu}\beta_{xt} + f(age_{iju}) + \epsilon_{iju} + \nu_{ju} \tag{4}$$

where $\hat{\eta_{ijt}}$ denotes the expected level of NHV without epidemic, ρ_{xu} models the relative change of a comorbidity effect compared to pre-epidemic, a separate age pattern during the epidemic was modeled with the RW2 term $f(age_{iju})$, and ν_{ju} denotes the country-specific change in the mean of the NHV during the epidemic. Similarly, for the post-epidemic period, we assumed that there might exist a carry-over effect of the pandemic and replaced the coefficients in Equation 4 with those representing the estimates from wave 9.

All equations were jointly estimated, using an augmented data approach and three likelihoods for the three data periods, in which the parameters were copied over to the epidemic and post-epidemic periods, including their uncertainty in the estimates [30].

There were three parts of the data, each of which yields a slightly different data likelihood. For the survey waves 1, 2, 4, and 5, SHARE recorded the NHV truncated at the value 98; during waves $6-9$, SHARE recorded the NHV without truncation; during the second COVID-19 survey, SHARE recorded the NHV as a binary response, which we interpreted as a Poisson variable truncated at one. The three parts can be modelled as a censored Poisson at 98, a Poisson, and a censored Poisson at one, respectively. The likelihood reads as

$$L = \prod_{ij} P(Y^{d=0} = y_{ij}) \prod P(Y^{d=1} \geq T_w) \tag{5}$$

where $d = 0, 1$ is an indicator whether the observation was censored; $T_w = \{1, 98\}$ denotes two cases of censored data described above. The model parameters were estimated with the R package INLA [31]. We computed posterior medians and 95% credible intervals of the outcomes of interests, including the annual NHV, the differential of the time trend, and the effect of COVID-19, using posterior simulations of 1000 parameter samples. The models were compared using the Watanabe Information Criteria (WAIC). Computations were done using the High Performance Computer Cluster at the Center for Scientific Computing (CSC) of the Goethe University Frankfurt with the single model runtime $\tilde{2}$6h on 40-cores 128Gb RAM AlmaLinux.

Results

Healthcare visits before the pandemic

Fig. 1 shows the expected annual number of healthcare visits by country and sex estimated for the year 2019, controlling for age, comorbidities, and trends over time. The nominal rate of visits, i.e., for an individual without comorbidites and of average age 75 years, varied from 1.5 visits to 5.6 visits per year, and was higher for women than for men. By 2019, the average NHV across countries was 3.5 for women and 3.0 for men. The highest rate of visits in 2019 was observed in the centre of Europe, with 5.6 nominal visit for women and 4.6 nominal visits for men in Luxembourg, followed by Belgium (women: 5.1, men: 4.3), Italy (women: 4.6, men: 4.0), Austria (women: 4.5,men: 4.0), and Germany (women: 4.5, men: 4.0). The lowest rate of visits was observed in Northern Europe and small islands, with 2.2 nominal visits for women and 2.0 nominal visits for men in Finland, followed by Cyprus (women: 2.6, men: 2.0), and Malta (women: 2.5, men: 2.2).

Across Europe, there was a large variation in trends in NHV over time, with a slight increase overall (Fig. S1). There was a small convergence, with countries with initially higher rates experiencing a smaller increase in the NHV than countries with initially lower rates (beta convergence men: -2.3%, p-value 0.081, beta convergence women: -2.4%, p-value 0.023). Within most countries, trends were relatively similar for women and men, while for some countries, such as Italy, Spain, France, and Czechia the gender gap in NHV narrowed over time.



Figure 1: Posterior estimate of the rate of healthcare visits annualised at the year 2019. The estimates are conditioned on the reference group in the regression model: no comorbidity and an average age (approx. 75)

Pandemic shock and recovery

Fig. 2 shows the estimated relative reduction of the healthcare visits rate during and after the COVID-19 pandemic by country. The estimates were derived from the difference between the expected rate if the pandemic had not occurred based on the pre-epidemic data. Individuals in all countries experienced a large drop in the rate of healthcare visits (Fig. 2); the least affected country was Germany with an estimated reduction of 55% for men and 58% for women. The most affected countries were Italy, Croatia, Estonia, and Hungary, where the healthcare visits came nearly to a halt with an estimated reduction of up to 95% in the NHV. In 2022, healthcare visits returned back to the pre-pandemic levels for most of the countries, with a NHV between 90% and 110% compared to prepandemic levels. The rate still remained low in Slovakia (men: 64%, women: 71%), Luxembourg (men: 81%, women: 85%), and Poland (men: 85%, women: 80%), and was relatively high compared to pre-pandemic levels in Cyprus (men: 136%, women: 114%).

We grouped the countries according to the government health expenditure as % of GDP in 2019. Countries with a very high health expenditure tended to have a smaller decline of healthcare visits during COVID-19, compared to those with a lower health expenditure. Overall, a 1 percentage point increase in government health expenditure as % of GDP in 2019 was correlated with a 4.7% higher NHV during the pandemic compared to pre-pandemic levels (i.e., a smaller reduction) for men and a 4.5% higher NHV during the pandemic compared to pre-pandemic levels for women. Neither the pandemic drop nor the post-pandemic recovery correlated with the severity of the pandemic (cumulative deaths or average Oxford Government Response stringency index by the time of the second COVID-19 survey), the population density in 2019, or the physician density in 2013. If Luxembourg, as an extreme outlier, was omitted, there was a negative correlation

between the pandemic decline and GDP p.c. in 2019.



Figure 2: Posterior estimate of the percentage reduction of the healthcare visits rate compared to what is expected by the past trend, the point and number are the posterior median, the lines are the 95% uncertainty interval. The countries are grouped by percent of domestic general government health expenditure of GDP for visualization purposes.

Healthcare visits across age and comorbidities

Fig. 3 shows that most chronic conditions were associated with a higher rate of healthcare visits. The largest difference in the rate of healthcare visits was among people with

cancer compared to people without cancer. Having chronic lung diseases, diabetes, a history of stroke, or heart attack was associated with an increase in the visit rate by approximately 20% compared to those without the disease. For most health conditions, the correlation was larger for men than for women. For stroke, stomach and related ulcers and high cholesterol, the correlation was similarly high for both sexes. During the epidemic period, the NHV decreased relatively more for most of the chronic conditions, but remained slightly higher than for respondents without a condition. After the pandemic, the correlation with NHV remained significantly lower for men with a prior heart attack (relative risk post-epidemic 1.30, 95% CI [1.29 – 1.31], pre-epidemic 1.48 [1.46 – 1.50]), hypertension (post: 1.29 [1.28 – 1.30], pre: 1.34 [1.33 – 1.36]), diabetes (post: 1.31 [1.29 – 1.32], pre: 1.43 [1.41 – 1.46]), and chronic lung disease (post: 1.29 [1.27 – 1.31], pre: 1.42 [1.39 – 1.44]), but was significantly higher for men with a cancer diagnosis (post: 1.90 [1.87 – 1.94], pre: 1.78 [1.75 – 1.81]) and stomach, duodenal, or peptic ulcer (post: 1.28 [1.24 – 1.32], pre: 1.19 [1.16 – 1.21]). For women, the picture was similar, except for ulcers: The correlation remained significantly lower for women with a prior heart attack (post: 1.30 [1.28 – 1.31], pre: 1.34 [1.32 – 1.36]), hypertension (post: 1.24 [1.23 – 1.25], pre: 1.29 [1.28 – 1.31], stroke (post: 1.21 [1.19 – 1.22], pre: 1.30 [1.26 – 1.32]), diabetes (post: 1.23 [1.22 – 1.25], pre: 1.34 [1.32 – 1.36]), and chronic lung disease (post: 1.27 [1.25 – 1.29], pre: 1.32 [1.30 – 1.34]), but significantly higher for cancer (post: 1.70 [1.67 – 1.72], pre: 1.62 [1.59 – 1.64]).

During the pre-epidemic period, age was positively linearly correlated with the number of visits, with a steeper trend for men compared to women. This pattern, however, changed during the epidemic into an inverse u-shaped relationship: For respondents aged 50-75, age was positively correlated with the NHV; but for respondents at higher ages, there was a steep negative correlation. After the pandemic, the positive linear correlation returned for both sexes, although with slightly flatter slopes, particularly for women.

Discussion

Evidence on the trajectories of healthcare visits after the pandemic is scarce for most European countries, especially for disaggregated data. We made use of a harmonized, longitudinal dataset of 147,116 individuals aged 50 and older in Europe, and found a large decline in the number of healthcare visits during the COVID-19 pandemic. While the extent of the decline differed across countries, age groups, and by prior diagnoses, the major share of the decline was reduced quickly after 2021. For people with prior diagnoses, relative disparities in the number of healthcare visits persisted, pointing towards a backlog in the healthcare systems. The pre-pandemic, positive age gradient in healthcare visits is in line with previous findings on the population aged 50 and older in Europe [32, 33]. The correlation might be driven by the accumulation of health deficits as people age [34], national screening guidelines, or might proxy time to death [35]. We found that during the pandemic, individuals above 75 reduced their healthcare visits more than proportionally, such that the age gradient reversed. At the same time, another study found that the incidence of missed healthcare visits due to fear of COVID-19, postponed,



Figure 3: Posterior estimate of the relative rate of healthcare visits by sex. The point/line and line range/shaded colours denote the posterior median and 95% uncertainty interval, respectively. The diseases and health conditions were compared against not being diagnosed with the respective condition. Age was modelled as nonlinear terms for each of the periods (pre, epi, post) separately.

or denied appointments, decreased with age [15]. This discrepancy might be explained either by the definition of "missed healthcare", which did not capture other reasons such as mobility restrictions or (perceived) recommendations to stay at home, especially given the higher risk of severe infections due to higher age, or by the respondents' perceptions, e.g. to which extent "fear" of infection drove the decision to not make an appointment. While the age gradient returned to a linear form after the pandemic, the correlation was flatter than before the pandemic, such that individuals at high ages faced a slightly lower relative NHV. The age gradient for the younger respondents remained quite similar during the pandemic, but the NHV were relatively higher after the pandemic, indicating a small catch-up effect for the population aged 50-60. This might point towards a backlog in general health checks and screenings, as this age group is at the brink (or just above) several screening guidelines [36, 37]. Indeed, findings from England show that blood pressure screening rates decreased for middle-aged individuals during the pandemic [38]. Previous studies on SHARE data primarily analysed the number of diagnoses of condition, or deficit indices containing diagnosed conditions, finding a positive correlation between multimorbidity and healthcare visits [39, 33, 40]. We showed that the difference in

healthcare visits among diagnosed and undiagnosed respondents was particularly high for cancer, and comparatively low for stomach and related ulcers and high cholesterol. During COVID-19, these associations decreased, resulting in a relatively larger gap in care for people with chronic conditions. There was no clear pattern according to the type of condition, e.g., whether patients were at high risk of a severe infection. The NHV increased more than proportionally for individuals with cancer after COVID-19, indicating that their conditions might have become more severe. This is similar to findings from the UK, where median attendance volume decreased for cancer patients during the lockdowns, followed by large increases in consultation rate afterwards [41]. At the same time, the NHV increased less than proportionally for (mostly) less acute conditions such as diabetes, hypertension, or a former heart attack or stroke, such that these individuals still experienced a gap in care compared to the time before the pandemic. Without further attention to ensure a full retention in care, these conditions are likely to worsen over time and induce higher healthcare costs in the medium run. Most European countries, as many countries worldwide, reacted to the onset of the pandemic with sudden and strict lockdown policies [28]. Yet, there was a large heterogeneity in the timing of large outbreaks, pandemic preparedness, and pandemic management, and finally in the excess mortality during the pandemic [42]. Health expenditure and GDP per capita, but not the average stringency index or population density were correlated with excess mortality [42], which mirrors our findings on NHV. Despite these heterogeneities, most countries returned to levels of healthcare visits similar to those before the pandemic.

Our study comes with several limitations. The number of healthcare visits measures healthcare access and utilization, but not necessarily whether utilization is adequate. As the number of objectively needed healthcare visits is individual and cannot be observed, we cannot distinguish between underutilization, adequate utilization, and overutilization. Hence, a higher rate of healthcare visits does not necessarily reflect better healthcare quality. Still, disparities in the rate of healthcare visits across groups and over time hint at potential deficits for one of the groups, and thus indicate the need for further investigation and potential policy intervention. Similarly, as healthcare visits are self-reported, we cannot rule out potential reporting biases common to survey data. Another limitation is the changed measurement of healthcare utilization during COVID-19. First, only the extensive margin, i.e., whether a doctor was visited, was assessed. Second, the phrasing of the question differed, as respondents were asked whether they went to a facility other than a hospital, compared to whether they have seen or talked to a doctor or nurse in the previous waves. We tried to incorporate these differences by modelling different Poisson distributions, but cannot rule out that this led to systematic differences in measurement which cannot be captured by the model. However, given that wave 9 returned to the previous questionnaire, we are confident that the reported post-COVID changes accurately reflect the difference to the pre-COVID period.

Overall, our findings suggest that while access to care largely returned to pre-pandemic levels for the population age 50+ in Europe and across countries, people at higher ages and with chronic conditions require more attention from research and policy making. Both groups were disproportionately affected in their access to care, despite being the groups most in need of regular healthcare visits. In the aftermath of this pandemic, their

retention-to-care needs to be ensured, and more monitoring might be required to detect health consequences of the disruption in care early on. For future pandemics, strategies are needed to ensure that disruptions in care are particularly monitored and buffered for those vulnerable groups.

Declarations

Author contributions

AR conceptualized the study, VKN developed the methods and analyzed the data. VKN and AR wrote the first draft of the manuscript. All authors reviewed and edited the final draft.

Acknowledgments

We acknowledge Jeff Imai-Eaton for suggesting the use of truncated Poisson to account for differences between normal waves and COVID waves.

This paper uses data from SHARE Waves 1, 2, 4, 5, 6, 7, 8 and 9 as well as SHARE Corona Survey 2 [16, 17, 18, 19, 20, 21, 22, 23, 24], see Börsch-Supan et al. (2013) and Scherpenzeel et al. (2020) for methodological details [43, 44]. The SHARE data collection has been funded by the European Commission, DG RTD through FP5 (QLK6-CT-2001-00360), FP6 (SHARE-I3: RII-CT-2006-062193, COMPARE: CIT5-CT-2005-028857, SHARELIFE: CIT4-CT-2006-028812), FP7 (SHAREPREP: GA N°211909, SHARE-LEAP: GA N°227822, SHARE M4: GA N°261982, DASISH: GA N°283646) and Horizon 2020 (SHARE-DEV3: GA N°676536, SHARE-COHESION: GA N°870628, SERISS: GA N°654221, SSHOC: GA N°823782) and by DG Employment, Social Affairs & Inclusion through VS 2015/0195, VS 2016/0135, VS 2018/0285, VS 2019/0332, and VS 2020/0313. Additional funding from the German Ministry of Education and Research, the Max Planck Society for the Advancement of Science, the U.S. National Institute on Aging (U01_AG09740-13S2, P01_AG005842, P01_AG08291, P30_AG12815, R21_AG025169, Y1-AG-4553-01, IAG_BSR06-11, OGHA_04–064, HHSN271201300071C, RAG052527A) and from various national funding sources is gratefully acknowledged (see https://share-eric.eu/).

Funding

Research in this article is a part of the European Union's H2020 SHARE COVID-19 project (Grant Agreement No. 101015924).

Ethical approval

The SHARE study was approved by the Ethics Committee at the University of Mannheim (waves 1-4) and by the Ethics Council of the Max-Planck-Society (waves 5-8). Additionally,

country-specific ethics committees or institutional review boards approved implementations of SHARE in the participating countries. All study participants provided informed consent.

Availability of data and materials

Access to the SHARE data can be applied for with the SHARE Research Data Center (https://share-eric.eu/data). Code will be made available at https://github.com/kklot/SHARE/.

References

[1] Ray Moynihan et al. "Covid-19: an opportunity to reduce unnecessary healthcare". In: *BMJ (Clinical research ed.)* 370 (2020), p. m2752. DOI: \url{10.1136/bmj.m2752}.

[2] Ray Moynihan et al. "Impact of COVID-19 pandemic on utilisation of healthcare services: a systematic review". In: *BMJ open* 11.3 (2021), e045343. DOI: \url{10.1136/bmjopen-2020-045343}.

[3] Charlotte M. Roy et al. "Assessing the indirect effects of COVID-19 on healthcare delivery, utilization and health outcomes: a scoping review". In: *European Journal of Public Health* 31.3 (2021), pp. 634–640. ISSN: 1101-1262. DOI: \url{10.1093/eurpub/ckab047}.

[4] Julien Dupraz, Marie-Annick Le Pogam, and Isabelle Peytremann-Bridevaux. "Early impact of the COVID-19 pandemic on in-person outpatient care utilisation: a rapid review". In: *BMJ open* 12.3 (2022), e056086. DOI: \url{10.1136/bmjopen-2021-056086}.

[5] Karen Tu et al. "Changes in primary care visits arising from the COVID-19 pandemic: an international comparative study by the International Consortium of Primary Care Big Data Researchers (INTRePID)". In: *BMJ open* 12.5 (2022), e059130. DOI: \url{10.1136/bmjopen-2021-059130}.

[6] Marco Angelini et al. "Decrease of cancer diagnosis during COVID-19 pandemic: a systematic review and meta-analysis". In: *European journal of epidemiology* 38.1 (2023), pp. 31–38. DOI: \url{10.1007/s10654-022-00946-6}.

[7] Richard Williams et al. "Diagnosis of physical and mental health conditions in primary care during the COVID-19 pandemic: a retrospective cohort study". In: *The Lancet. Public health* 5.10 (2020), e543–e550. DOI: \url{10.1016/S2468-2667(20)30201-2}.

[8] Yasmine Khan et al. "Impact of the COVID-19 pandemic on delayed care of cardiovascular diseases in Europe: a systematic review". In: *Lancet (London, England)* 402 Suppl 1 (2023), S61. DOI: \url{10.1016/S0140-6736(23)02117-7}.

[9] Lara V. Maul et al. "Health Economic Consequences Associated With COVID-19-Related Delay in Melanoma Diagnosis in Europe". In: *JAMA network open* 7.2 (2024), e2356479. DOI: \url{10.1001/jamanetworkopen.2023.56479}.

[10] Vicky P. Taxiarchi et al. "Changes to healthcare utilisation and symptoms for common mental health problems over the first 21 months of the COVID-19 pandemic: parallel analyses of electronic health records and survey data in England". In: *The Lancet Regional Health - Europe* 32 (2023), p. 100697. ISSN: 26667762. DOI: \url{10.1016/j.lanepe.2023.100697}.

[11] Yong Du et al. "Outpatient Health Service Utilization Among Adults with Diabetes, Hypertension and Cardiovascular Disease During the COVID-19 Pandemic - Results of Population-Based Surveys in Germany from 2019 to 2021". In: *Journal of multidisciplinary healthcare* 17 (2024), pp. 675–687. ISSN: 1178-2390. DOI: \url{10.2147/JMDH.S445899}.

[12] Magdalena Mrożek-Gąsiorowska and Marzena Tambor. "How COVID-19 has changed the utilization of different health care services in Poland". In: *BMC health services research* 24.1 (2024), p. 105. DOI: \url{10.1186/s12913-024-10554-7}.

[13] Oskar Niemenoja et al. "The impact of COVID-19 on healthcare booking and cancellation patterns: time series analysis of private healthcare service utilisation in Finland". In: *BMC health services research* 24.1 (2024), p. 483. DOI: \url{10.1186/s12913-024-10987-0}.

[14] Christopher Alba, ZhaoNian Zheng, and Rishi K. Wadhera. "Changes in Health Care Access and Preventive Health Screenings by Race and Ethnicity". In: *JAMA health forum* 5.2 (2024), e235058. DOI: \url{10.1001/jamahealthforum.2023.5058}.

[15] Šime Smolić, Ivan Čipin, and Petra Međimurec. "Access to healthcare for people aged 50+ in Europe during the COVID-19 outbreak". In: *European journal of ageing* 19.4 (2022), pp. 793–809. ISSN: 1613-9372. DOI: \url{10.1007/s10433-021-00631-9}.

[16] SHARE-ERIC. *Survey of Health, Ageing and Retirement in Europe (SHARE) Wave 1*. 2024. DOI: \url{10.6103/SHARE.W1.900}.

[17] SHARE-ERIC. *Survey of Health, Ageing and Retirement in Europe (SHARE) Wave 2*. 2024. DOI: \url{10.6103/SHARE.w2.900}.

[18] SHARE-ERIC. *Survey of Health, Ageing and Retirement in Europe (SHARE) Wave 4*. 2024. DOI: \url{10.6103/SHARE.w4.900}.

[19] SHARE-ERIC. *Survey of Health, Ageing and Retirement in Europe (SHARE) Wave 5*. 2024. DOI: \url{10.6103/SHARE.w5.900}.

[20] SHARE-ERIC. *Survey of Health, Ageing and Retirement in Europe (SHARE) Wave 6*. 2024. DOI: \url{10.6103/SHARE.w6.900}.

[21] SHARE-ERIC. *Survey of Health, Ageing and Retirement in Europe (SHARE) Wave 7*. 2024. DOI: \url{10.6103/SHARE.w7.900}.

[22] SHARE-ERIC. *Survey of Health, Ageing and Retirement in Europe (SHARE) Wave 8*. 2024. DOI: \url{10.6103/SHARE.w8.900}.

[23] SHARE-ERIC. *Survey of Health, Ageing and Retirement in Europe (SHARE) Wave 9*. 2024. DOI: \url{10.6103/SHARE.w9.900}.

[24] SHARE-ERIC. *Survey of Health, Ageing and Retirement in Europe (SHARE) Wave 9. COVID-19 Survey 2*. 2024. DOI: \url{10.6103/SHARE.w9ca.900}.

[25] World Bank. *World Development Indicators database*. 2022.

[26] World Health Organization. *Global Health Expenditure database*. 2022.

[27] WHO Regional Office for Europe 2022. *European Health for All database (HFA-DB)*. Sept. 2022. URL: https://gateway.euro.who.int/en/datasets/european-health-for-all-database/.

[28] Thomas Hale et al. "A global panel database of pandemic policies (Oxford COVID-19 Government Response Tracker)". In: *Nature Human Behaviour* 5.4 (Apr. 2021). Number: 4 Publisher: Nature Publishing Group, pp. 529–538. ISSN: 2397-3374. DOI: 10.1038/s41562-021-01079-8. URL: https://www.nature.com/articles/s41562-021-01079-8 (visited on 08/24/2022).

[29] Julian Besag, Jeremy York, and Annie Mollié. "Bayesian Image Restoration, with Two Applications in Spatial Statistics". In: *Annals of the Institute of Statistical Mathematics* 43.1 (Mar. 1, 1991), pp. 1–20. ISSN: 1572-9052. DOI: 10.1007/BF00116466. URL: https://doi.org/10.1007/BF00116466 (visited on 11/21/2023).

[30] Thiago G. Martins et al. "Bayesian Computing with INLA: New Features". In: *Computational Statistics and Data Analysis* 67 (Nov. 2013), pp. 68–83. ISSN: 01679473. DOI: 10.1016/j.csda.2013.04.014. URL: https://www.sciencedirect.com/science/article/pii/S0167947313001552%20http://dx.doi.org/10.1016/j.csda.2013.04.014.

[31] Håvard Rue, Sara Martino, and Nicolas Chopin. "Approximate Bayesian Inference for Latent Gaussian Models by Using Integrated Nested Laplace Approximations". In: *Journal of the Royal Statistical Society: Series B (Statistical Methodology)* 71.2 (2009), pp. 319–392. ISSN: 1467-9868. DOI: 10.1111/j.1467-9868.2008.00700.x. URL: https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1467-9868.2008.00700.x (visited on 11/22/2023).

[32] Florence Jusot, Zeynep Or, and Nicolas Sirven. "Variations in preventive care utilisation in Europe". en. In: *European Journal of Ageing* 9.1 (Mar. 2012), pp. 15–25. ISSN: 1613-9380. DOI: 10.1007/s10433-011-0201-9. URL: https://doi.org/10.1007/s10433-011-0201-9 (visited on 10/19/2022).

[33] Marco Terraneo. "Inequities in health care utilization by people aged 50+: Evidence from 12 European countries". en. In: *Social Science & Medicine* 126 (Feb. 2015), pp. 154–163. ISSN: 0277-9536. DOI: 10.1016/j.socscimed.2014.12.028. URL: https://www.sciencedirect.com/science/article/pii/S0277953614008363 (visited on 10/19/2022).

[34] Ana Lucia Abeliansky and Holger Strulik. "How We Fall Apart: Similarities of Human Aging in 10 European Countries". In: *Demography* 55.1 (Jan. 2018), pp. 341–359. ISSN: 0070-3370. DOI: 10.1007/s13524-017-0641-8. URL: https://doi.org/10.1007/s13524-017-0641-8 (visited on 04/18/2023).

[35] Joan Costa-Font and Cristina Vilaplana-Prieto. "'More than one red herring'? Heterogeneous effects of ageing on health care utilisation". en. In: *Health Economics* 29.S1 (Oct. 2020), pp. 8–29. ISSN: 1057-9230, 1099-1050. DOI: 10.1002/hec.4035. URL: https://onlinelibrary.wiley.com/doi/10.1002/hec.4035 (visited on 08/24/2022).

[36] Frank L. J. Visseren et al. "2021 ESC Guidelines on cardiovascular disease prevention in clinical practice". In: *European heart journal* 42.34 (2021), pp. 3227–3337. DOI: \url{10.1093/eurheartj/ehab484}.

[37] Holger J. Schünemann et al. "Breast Cancer Screening and Diagnosis: A Synopsis of the European Breast Guidelines". In: *Annals of Internal Medicine* 172.1 (2020), pp. 46–56. DOI: \url{10.7326/M19-2125}.

[38] Milan Wiedemann et al. "Impact of COVID-19 on recorded blood pressure screening and hypertension management in England: an analysis of monthly changes in the quality and outcomes framework indicators in OpenSAFELY". In: *Open heart* 11.2 (2024). ISSN: 2053-3624. DOI: \url{10.1136/openhrt-2024-002732}.

[39] Raffaele Palladino et al. "Associations between multimorbidity, healthcare utilisation and health status: evidence from 16 European countries". In: *Age and Ageing* 45.3 (May 2016), pp. 431–435. ISSN: 0002-0729. DOI: 10.1093/ageing/afw044. URL: https://doi.org/10.1093/ageing/afw044 (visited on 10/19/2022).

[40] Stefania Ilinca and Stefano Calciolari. "The Patterns of Health Care Utilization by Elderly Europeans: Frailty and Its Implications for Health Systems". en. In: *Health Services Research* 50.1 (2015). _eprint: https://onlinelibrary.wiley.com/doi/pdf/10.1111/1475-6773.12211, pp. 305–320. ISSN: 1475-6773. DOI: 10.1111/1475-6773.12211. URL: https://onlinelibrary.wiley.com/doi/abs/10.1111/1475-6773.12211 (visited on 10/19/2022).

[41] Yen Yi Tan et al. "Impact of the COVID-19 pandemic on health-care use among patients with cancer in England, UK: a comprehensive phase-by-phase time-series analysis across attendance types for 38 cancers". In: *The Lancet Digital Health* 6.10 (2024), e691–e704. ISSN: 2589-7500. DOI: \url{10.1016/S2589-7500(24)00152-3}.

[42] Margherita Pizzato et al. "Impact of COVID-19 on total excess mortality and geographic disparities in Europe, 2020–2023: a spatio-temporal analysis". In: *The Lancet Regional Health - Europe* 44 (2024), p. 100996. ISSN: 26667762. DOI: \url{10.1016/j.lanepe.2024.100996}.

[43] Axel Börsch-Supan et al. "Data Resource Profile: the Survey of Health, Ageing and Retirement in Europe (SHARE)". In: *International journal of epidemiology* 42.4 (2013), pp. 992–1001. DOI: \url{10.1093/ije/dyt088}.

[44] Annette Scherpenzeel et al. "Collecting survey data among the 50+ population during the COVID-19 outbreak: The Survey of Health, Ageing and Retirement in Europe (SHARE)". In: *Survey Research Methods* 14.2 (2020), pp. 217–221. DOI: \url{10.18148/SRM/2020.V14I2.7738}.

Supplemental Information

Survey questions related to the outcome

The following questions were used to collect the number of healthcare visits.

Table S1: Survey questions on number of healthcare visits

Wave	Question	Variable
1,2,4,5	Now please think about the last 12 months. About how many times in total have you seen or talked to a medical doctor or qualified nurse about your health? Please exclude dentist visits and hospital stays, but include emergency room or outpatient clinic visits.	hc002_
6–8	Now please think about the last 12 months. Since {month & year of last visit} about how many times in total have you seen or talked to a medical doctor or qualified/registered nurse about your health? Please exclude dentist visits and hospital stays, but include emergency room or outpatient clinic visits.	hc602_
COVID II	Since last year/since last visit, did you go to a doctor's office or a medical facility other than a hospital?	caq120_

Pre-pandemic trends in NHV

Figure S1: Posterior estimate of the annual rate of healthcare visits over time from 2004 to 2019. the line and its colour shade are the posterior median and 95% uncertainty interval. The estimates are conditioned on the reference group in the regression model: no comorbidities, an average age (approx. 75).

Detailed estimates

Table S2: Estimate NHV by country and sex from 2004-2019

year	country	sex	0.025quant	median	0.975quant
2004	Austria	male	3.244199	3.460106	3.662921
2005	Austria	male	3.284774	3.494889	3.680657
2006	Austria	male	3.325859	3.530927	3.704924
2007	Austria	male	3.379521	3.564859	3.721738
2008	Austria	male	3.425780	3.601352	3.740787
2009	Austria	male	3.464312	3.635793	3.764271
2010	Austria	male	3.503291	3.667981	3.795868
2011	Austria	male	3.551597	3.698551	3.832392
2012	Austria	male	3.594402	3.729973	3.870946
2013	Austria	male	3.633689	3.765922	3.905992
2014	Austria	male	3.665187	3.799657	3.947811
2015	Austria	male	3.694690	3.828295	3.994102
2016	Austria	male	3.730863	3.860150	4.041881
2017	Austria	male	3.762956	3.899215	4.082895
2018	Austria	male	3.782890	3.937422	4.138312
2019	Austria	male	3.800858	3.970442	4.201758
2020	Austria	male	3.823528	4.011040	4.259771
2021	Austria	male	3.847863	4.045841	4.321583
2022	Austria	male	3.867877	4.084259	4.384417
2017	Bulgaria	male	2.324126	2.464562	2.646342
2018	Bulgaria	male	2.404520	2.554225	2.722185
2019	Bulgaria	male	2.452132	2.643808	2.863810
2020	Bulgaria	male	2.481193	2.733460	3.012805
2021	Bulgaria	male	2.498934	2.817244	3.185286
2022	Bulgaria	male	2.516650	2.904888	3.395005
2004	Belgium	male	3.883873	4.034797	4.216610
2005	Belgium	male	3.909189	4.049865	4.215877
2006	Belgium	male	3.931470	4.060354	4.220124
2007	Belgium	male	3.952495	4.074560	4.233116
2008	Belgium	male	3.973634	4.088359	4.241866
2009	Belgium	male	3.995887	4.105081	4.249627
2010	Belgium	male	4.020443	4.123086	4.258893
2011	Belgium	male	4.046720	4.139696	4.272074
2012	Belgium	male	4.063808	4.154753	4.291558

(Continued on Next Page...)

Table S2: Estimate NHV by country and sex from 2004-2019 *(continued)*

year	country	sex	0.025quant	median	0.975quant
2013	Belgium	male	4.075209	4.171062	4.310870
2014	Belgium	male	4.082016	4.186349	4.325396
2015	Belgium	male	4.086260	4.202507	4.338838
2016	Belgium	male	4.085840	4.220226	4.354893
2017	Belgium	male	4.084775	4.236993	4.372816
2018	Belgium	male	4.083713	4.255554	4.393480
2019	Belgium	male	4.084788	4.263544	4.412957
2020	Belgium	male	4.085892	4.280969	4.436063
2021	Belgium	male	4.086998	4.297879	4.462347
2022	Belgium	male	4.088104	4.316731	4.490359
2017	Cyprus	male	1.753463	1.918135	2.113676
2018	Cyprus	male	1.824660	1.977191	2.169034
2019	Cyprus	male	1.865503	2.020889	2.230358
2020	Cyprus	male	1.854917	2.060596	2.317932
2021	Cyprus	male	1.844275	2.101663	2.476660
2022	Cyprus	male	1.816015	2.158657	2.627885
2006	Czechia	male	3.756379	3.965727	4.164976
2007	Czechia	male	3.770497	3.959211	4.134229
2008	Czechia	male	3.775132	3.951706	4.113152
2009	Czechia	male	3.781073	3.947550	4.093206
2010	Czechia	male	3.795763	3.935216	4.073388
2011	Czechia	male	3.802267	3.925542	4.058503
2012	Czechia	male	3.808273	3.916208	4.043924
2013	Czechia	male	3.807268	3.904517	4.032663
2014	Czechia	male	3.800561	3.897899	4.026677
2015	Czechia	male	3.796258	3.898441	4.021133
2016	Czechia	male	3.782812	3.895919	4.023218
2017	Czechia	male	3.763977	3.894924	4.021260
2018	Czechia	male	3.741245	3.892757	4.015659
2019	Czechia	male	3.717177	3.883397	4.015749
2020	Czechia	male	3.687792	3.878948	4.016611
2021	Czechia	male	3.661408	3.869957	4.017663
2022	Czechia	male	3.645380	3.862802	4.021453
2004	Switzerland	male	2.285286	2.411575	2.567788
2005	Switzerland	male	2.322030	2.443835	2.585608
2006	Switzerland	male	2.356833	2.475897	2.603658

(Continued on Next Page...)

Table S2: Estimate NHV by country and sex from 2004-2019 *(continued)*

year	country	sex	0.025quant	median	0.975quant
2007	Switzerland	male	2.392161	2.508115	2.622516
2008	Switzerland	male	2.428021	2.542401	2.649753
2009	Switzerland	male	2.464422	2.573775	2.679486
2010	Switzerland	male	2.502315	2.608691	2.709556
2011	Switzerland	male	2.542152	2.639242	2.740295
2012	Switzerland	male	2.585467	2.674719	2.771421
2013	Switzerland	male	2.628621	2.706673	2.807531
2014	Switzerland	male	2.667996	2.740811	2.848302
2015	Switzerland	male	2.702294	2.778900	2.886063
2016	Switzerland	male	2.723814	2.815149	2.924014
2017	Switzerland	male	2.752536	2.858882	2.971912
2018	Switzerland	male	2.788323	2.895651	3.020335
2019	Switzerland	male	2.823681	2.930536	3.069547
2020	Switzerland	male	2.859364	2.971176	3.119562
2021	Switzerland	male	2.895475	3.016268	3.170393
2022	Switzerland	male	2.925196	3.052734	3.222053
2004	Germany	male	3.880529	4.083841	4.217659
2005	Germany	male	3.891122	4.078301	4.200999
2006	Germany	male	3.899053	4.070844	4.186233
2007	Germany	male	3.900183	4.062363	4.172630
2008	Germany	male	3.901369	4.052025	4.160039
2009	Germany	male	3.912579	4.041371	4.147488
2010	Germany	male	3.917304	4.030796	4.136068
2011	Germany	male	3.919616	4.024849	4.128607
2012	Germany	male	3.911728	4.014345	4.125191
2013	Germany	male	3.905226	4.005981	4.115022
2014	Germany	male	3.892991	4.000654	4.108248
2015	Germany	male	3.879362	3.998325	4.106003
2016	Germany	male	3.863147	3.998550	4.107122
2017	Germany	male	3.846830	3.991262	4.113633
2018	Germany	male	3.827880	3.983048	4.125389
2019	Germany	male	3.810506	3.976494	4.134874
2020	Germany	male	3.794603	3.972071	4.146742
2021	Germany	male	3.772015	3.964498	4.158903
2022	Germany	male	3.748775	3.960792	4.171105
2004	Denmark	male	2.113838	2.229624	2.344852

(Continued on Next Page...)

Table S2: Estimate NHV by country and sex from 2004-2019 *(continued)*

year	country	sex	0.025quant	median	0.975quant
2005	Denmark	male	2.155025	2.261982	2.370705
2006	Denmark	male	2.196922	2.294652	2.400002
2007	Denmark	male	2.234987	2.328285	2.429858
2008	Denmark	male	2.273205	2.360738	2.457329
2009	Denmark	male	2.308850	2.396298	2.486311
2010	Denmark	male	2.339886	2.432487	2.517746
2011	Denmark	male	2.371347	2.468042	2.549649
2012	Denmark	male	2.408790	2.506387	2.582297
2013	Denmark	male	2.451103	2.543085	2.623545
2014	Denmark	male	2.492376	2.581734	2.664210
2015	Denmark	male	2.526747	2.619157	2.709997
2016	Denmark	male	2.559962	2.656521	2.759732
2017	Denmark	male	2.596059	2.696212	2.810565
2018	Denmark	male	2.632531	2.737158	2.861284
2019	Denmark	male	2.669349	2.774810	2.912520
2020	Denmark	male	2.703145	2.815101	2.964678
2021	Denmark	male	2.735676	2.857313	3.017773
2022	Denmark	male	2.768526	2.898941	3.071823
2010	Estonia	male	2.285376	2.407619	2.515785
2011	Estonia	male	2.321620	2.435062	2.531984
2012	Estonia	male	2.354188	2.461547	2.554775
2013	Estonia	male	2.387216	2.485227	2.576618
2014	Estonia	male	2.420712	2.508629	2.607167
2015	Estonia	male	2.451066	2.532520	2.639991
2016	Estonia	male	2.482253	2.560670	2.662277
2017	Estonia	male	2.500171	2.588182	2.691715
2018	Estonia	male	2.512945	2.617084	2.728164
2019	Estonia	male	2.521022	2.649383	2.765736
2020	Estonia	male	2.533602	2.680576	2.809078
2021	Estonia	male	2.546200	2.709136	2.856455
2022	Estonia	male	2.558527	2.742129	2.904632
2004	Spain	male	3.347348	3.498001	3.688898
2005	Spain	male	3.297239	3.432552	3.613407
2006	Spain	male	3.246230	3.369188	3.537009
2007	Spain	male	3.194815	3.311524	3.459134
2008	Spain	male	3.142192	3.259413	3.377703

(Continued on Next Page...)

Table S2: Estimate NHV by country and sex from 2004-2019 *(continued)*

year	country	sex	0.025quant	median	0.975quant
2009	Spain	male	3.090435	3.200742	3.300218
2010	Spain	male	3.039625	3.144317	3.231704
2011	Spain	male	2.989466	3.088112	3.171840
2012	Spain	male	2.939894	3.033418	3.117152
2013	Spain	male	2.889127	2.982913	3.061398
2014	Spain	male	2.839237	2.925885	3.008013
2015	Spain	male	2.790210	2.870999	2.951013
2016	Spain	male	2.740510	2.822379	2.903303
2017	Spain	male	2.690462	2.771261	2.858577
2018	Spain	male	2.641328	2.722688	2.813158
2019	Spain	male	2.586018	2.674989	2.769134
2020	Spain	male	2.528921	2.628114	2.727162
2021	Spain	male	2.475114	2.581005	2.686196
2022	Spain	male	2.422000	2.534916	2.645852
2004	France	male	3.954110	4.101470	4.299594
2005	France	male	3.902900	4.035913	4.220847
2006	France	male	3.852355	3.969498	4.143909
2007	France	male	3.799137	3.908429	4.070009
2008	France	male	3.750196	3.854564	4.000267
2009	France	male	3.697364	3.798958	3.929466
2010	France	male	3.645561	3.741282	3.860323
2011	France	male	3.589038	3.685064	3.792560
2012	France	male	3.529655	3.625250	3.725994
2013	France	male	3.469672	3.564048	3.667587
2014	France	male	3.410708	3.510265	3.618347
2015	France	male	3.352746	3.452330	3.568869
2016	France	male	3.295770	3.393085	3.518156
2017	France	male	3.239762	3.342080	3.460407
2018	France	male	3.184701	3.286363	3.407942
2019	France	male	3.130243	3.235844	3.357987
2020	France	male	3.075435	3.182166	3.309031
2021	France	male	3.022239	3.133501	3.263499
2022	France	male	2.968287	3.086178	3.221732
2017	Finland	male	1.776112	1.912624	2.029705
2018	Finland	male	1.828131	1.937079	2.073979
2019	Finland	male	1.838486	1.963458	2.120321

(Continued on Next Page...)

Table S2: Estimate NHV by country and sex from 2004-2019 *(continued)*

year	country	sex	0.025quant	median	0.975quant
2020	Finland	male	1.821745	1.989490	2.217819
2021	Finland	male	1.797792	2.022566	2.329718
2022	Finland	male	1.762212	2.061379	2.437676
2004	Greece	male	2.336756	2.455857	2.546893
2005	Greece	male	2.327260	2.437612	2.520586
2006	Greece	male	2.320755	2.420404	2.496679
2007	Greece	male	2.310035	2.401591	2.473771
2008	Greece	male	2.295108	2.383327	2.451333
2009	Greece	male	2.282930	2.364572	2.431897
2010	Greece	male	2.270677	2.345659	2.414553
2011	Greece	male	2.255879	2.325607	2.397333
2012	Greece	male	2.239666	2.306747	2.380236
2013	Greece	male	2.222699	2.288724	2.366024
2014	Greece	male	2.203847	2.269812	2.351651
2015	Greece	male	2.184191	2.255534	2.330872
2016	Greece	male	2.163298	2.237645	2.318205
2017	Greece	male	2.142575	2.221655	2.305785
2018	Greece	male	2.121995	2.202893	2.293656
2019	Greece	male	2.101430	2.183801	2.281607
2020	Greece	male	2.080759	2.166986	2.271962
2021	Greece	male	2.060125	2.148391	2.260097
2022	Greece	male	2.039696	2.129329	2.249710
2015	Croatia	male	2.818899	2.963210	3.125338
2016	Croatia	male	2.931890	3.079602	3.211470
2017	Croatia	male	3.061638	3.202042	3.325886
2018	Croatia	male	3.162173	3.327052	3.474513
2019	Croatia	male	3.266322	3.459496	3.634036
2020	Croatia	male	3.348277	3.588136	3.809929
2021	Croatia	male	3.420714	3.723385	3.987053
2022	Croatia	male	3.504930	3.868867	4.182924
2011	Hungary	male	3.737053	3.961451	4.198961
2012	Hungary	male	3.694354	3.912721	4.111955
2013	Hungary	male	3.655128	3.845653	4.035131
2014	Hungary	male	3.603356	3.786226	3.994130
2015	Hungary	male	3.547816	3.738637	3.937473
2016	Hungary	male	3.493081	3.678122	3.891035

(Continued on Next Page...)

Table S2: Estimate NHV by country and sex from 2004-2019 *(continued)*

year	country	sex	0.025quant	median	0.975quant
2017	Hungary	male	3.433541	3.628272	3.849194
2018	Hungary	male	3.377104	3.581787	3.819606
2019	Hungary	male	3.310496	3.527093	3.811497
2020	Hungary	male	3.239111	3.476036	3.801276
2021	Hungary	male	3.159718	3.423566	3.781077
2022	Hungary	male	3.082273	3.373404	3.761957
2004	Italy	male	3.638012	3.792002	3.940272
2005	Italy	male	3.655998	3.804094	3.945304
2006	Italy	male	3.677391	3.817871	3.950347
2007	Italy	male	3.701692	3.826553	3.955567
2008	Italy	male	3.721287	3.836572	3.966581
2009	Italy	male	3.742348	3.855299	3.981572
2010	Italy	male	3.755036	3.870574	3.993130
2011	Italy	male	3.762534	3.881574	4.003240
2012	Italy	male	3.774827	3.893342	4.013815
2013	Italy	male	3.785281	3.909547	4.033153
2014	Italy	male	3.793788	3.923897	4.053603
2015	Italy	male	3.802878	3.939104	4.068472
2016	Italy	male	3.814293	3.951878	4.083120
2017	Italy	male	3.819651	3.966996	4.105077
2018	Italy	male	3.820580	3.983181	4.129362
2019	Italy	male	3.821325	3.998240	4.153798
2020	Italy	male	3.822070	4.016486	4.178386
2021	Italy	male	3.822815	4.029089	4.203538
2022	Italy	male	3.823559	4.043919	4.228974
2017	Lithuania	male	1.966791	2.161937	2.320051
2018	Lithuania	male	2.119839	2.294761	2.443565
2019	Lithuania	male	2.257654	2.431049	2.598693
2020	Lithuania	male	2.367347	2.583298	2.808093
2021	Lithuania	male	2.480978	2.745333	3.056385
2022	Lithuania	male	2.573293	2.914560	3.359269
2013	Luxembourg	male	3.629288	3.914485	4.153103
2014	Luxembourg	male	3.750787	4.008530	4.237594
2015	Luxembourg	male	3.863161	4.127877	4.337275
2016	Luxembourg	male	3.978641	4.238819	4.469403
2017	Luxembourg	male	4.095715	4.367421	4.622146

(Continued on Next Page...)

Table S2: Estimate NHV by country and sex from 2004-2019 *(continued)*

year	country	sex	0.025quant	median	0.975quant
2018	Luxembourg	male	4.199950	4.488704	4.750377
2019	Luxembourg	male	4.303494	4.618392	4.900402
2020	Luxembourg	male	4.399428	4.755745	5.124929
2021	Luxembourg	male	4.480262	4.896041	5.323812
2022	Luxembourg	male	4.571260	5.014299	5.529228
2017	Latvia	male	2.057815	2.223410	2.417324
2018	Latvia	male	2.183627	2.330396	2.513813
2019	Latvia	male	2.256063	2.440169	2.665699
2020	Latvia	male	2.291690	2.559015	2.888447
2021	Latvia	male	2.315060	2.680334	3.102717
2022	Latvia	male	2.339417	2.810347	3.348298
2017	Malta	male	2.069205	2.245738	2.423255
2018	Malta	male	2.053578	2.213989	2.392156
2019	Malta	male	2.010926	2.183875	2.366208
2020	Malta	male	1.932824	2.161301	2.377905
2021	Malta	male	1.869101	2.129763	2.428568
2022	Malta	male	1.795742	2.104780	2.473381
2004	Netherlands	male	2.341247	2.445362	2.574740
2005	Netherlands	male	2.385838	2.488632	2.612018
2006	Netherlands	male	2.430836	2.532519	2.655612
2007	Netherlands	male	2.485407	2.576640	2.694141
2008	Netherlands	male	2.539309	2.624417	2.731684
2009	Netherlands	male	2.589852	2.670062	2.771262
2010	Netherlands	male	2.636201	2.715317	2.813063
2011	Netherlands	male	2.679952	2.761771	2.856186
2012	Netherlands	male	2.720350	2.812735	2.902204
2013	Netherlands	male	2.763426	2.860812	2.950651
2014	Netherlands	male	2.807184	2.913119	3.008147
2015	Netherlands	male	2.851116	2.969082	3.067172
2016	Netherlands	male	2.891873	3.022309	3.129340
2017	Netherlands	male	2.931165	3.073998	3.194306
2018	Netherlands	male	2.971659	3.125741	3.263563
2019	Netherlands	male	3.018083	3.183243	3.335922
2020	Netherlands	male	3.065121	3.238432	3.415960
2021	Netherlands	male	3.112610	3.293271	3.497872
2022	Netherlands	male	3.159560	3.348987	3.570559

(Continued on Next Page...)

Table S2: Estimate NHV by country and sex from 2004-2019 *(continued)*

year	country	sex	0.025quant	median	0.975quant
2006	Poland	male	3.177556	3.363993	3.611440
2007	Poland	male	3.185707	3.351467	3.578940
2008	Poland	male	3.189846	3.337737	3.546882
2009	Poland	male	3.193583	3.327522	3.517528
2010	Poland	male	3.200949	3.314843	3.484600
2011	Poland	male	3.207288	3.303818	3.455098
2012	Poland	male	3.207839	3.300330	3.431305
2013	Poland	male	3.203941	3.288313	3.408860
2014	Poland	male	3.199674	3.279612	3.395817
2015	Poland	male	3.189393	3.267826	3.385257
2016	Poland	male	3.172290	3.263330	3.375812
2017	Poland	male	3.153659	3.248354	3.375024
2018	Poland	male	3.131477	3.234993	3.368743
2019	Poland	male	3.105822	3.225807	3.366856
2020	Poland	male	3.080379	3.216849	3.369025
2021	Poland	male	3.054464	3.208562	3.374845
2022	Poland	male	3.025946	3.198320	3.382920
2011	Portugal	male	2.272455	2.401393	2.579618
2012	Portugal	male	2.302620	2.407835	2.569256
2013	Portugal	male	2.307798	2.412541	2.566413
2014	Portugal	male	2.308548	2.429650	2.564225
2015	Portugal	male	2.307666	2.439369	2.576635
2016	Portugal	male	2.302540	2.450754	2.603310
2017	Portugal	male	2.286131	2.460403	2.633796
2018	Portugal	male	2.267427	2.469431	2.664843
2019	Portugal	male	2.245716	2.478152	2.698444
2020	Portugal	male	2.216033	2.490652	2.747678
2021	Portugal	male	2.182451	2.508151	2.805644
2022	Portugal	male	2.156685	2.522416	2.854331
2017	Romania	male	1.865088	1.984371	2.130991
2018	Romania	male	1.989411	2.103079	2.256252
2019	Romania	male	2.068890	2.233734	2.402204
2020	Romania	male	2.141704	2.364406	2.579603
2021	Romania	male	2.213788	2.505229	2.785167
2022	Romania	male	2.303017	2.659305	3.013512
2004	Sweden	male	1.448451	1.523429	1.611074

(Continued on Next Page...)

Table S2: Estimate NHV by country and sex from 2004-2019 *(continued)*

year	country	sex	0.025quant	median	0.975quant
2005	Sweden	male	1.498871	1.572926	1.656019
2006	Sweden	male	1.551047	1.623066	1.702220
2007	Sweden	male	1.604913	1.674941	1.748121
2008	Sweden	male	1.660805	1.728399	1.797049
2009	Sweden	male	1.720712	1.783870	1.847507
2010	Sweden	male	1.780412	1.841917	1.899388
2011	Sweden	male	1.840181	1.901901	1.953293
2012	Sweden	male	1.897795	1.962628	2.012525
2013	Sweden	male	1.958306	2.025201	2.078350
2014	Sweden	male	2.016908	2.091179	2.147002
2015	Sweden	male	2.081239	2.158060	2.211285
2016	Sweden	male	2.146044	2.227174	2.280271
2017	Sweden	male	2.212870	2.301468	2.355540
2018	Sweden	male	2.280838	2.375196	2.436340
2019	Sweden	male	2.346240	2.451948	2.518284
2020	Sweden	male	2.412804	2.531435	2.607695
2021	Sweden	male	2.481146	2.615391	2.698335
2022	Sweden	male	2.552238	2.700723	2.793456
2011	Slovenia	male	2.539055	2.662643	2.835017
2012	Slovenia	male	2.574255	2.688518	2.837687
2013	Slovenia	male	2.609459	2.707287	2.847667
2014	Slovenia	male	2.642271	2.735856	2.848931
2015	Slovenia	male	2.672911	2.754136	2.855295
2016	Slovenia	male	2.688128	2.775179	2.879561
2017	Slovenia	male	2.700513	2.790653	2.903197
2018	Slovenia	male	2.709785	2.821380	2.934738
2019	Slovenia	male	2.717089	2.842528	2.981454
2020	Slovenia	male	2.724286	2.866570	3.027800
2021	Slovenia	male	2.727186	2.881719	3.075243
2022	Slovenia	male	2.722732	2.899404	3.123445
2017	Slovakia	male	2.691845	2.876603	3.078890
2018	Slovakia	male	2.995293	3.166089	3.366906
2019	Slovakia	male	3.271768	3.484018	3.741000
2020	Slovakia	male	3.551516	3.842132	4.172829
2021	Slovakia	male	3.829498	4.235402	4.704391
2022	Slovakia	male	4.128872	4.680766	5.314641

(Continued on Next Page...)

Table S2: Estimate NHV by country and sex from 2004-2019 *(continued)*

year	country	sex	0.025quant	median	0.975quant
2004	Austria	female	3.735494	3.915671	4.110365
2005	Austria	female	3.784077	3.957955	4.132839
2006	Austria	female	3.833354	4.001247	4.156065
2007	Austria	female	3.883275	4.045384	4.186932
2008	Austria	female	3.933680	4.082222	4.220465
2009	Austria	female	3.988576	4.121603	4.254267
2010	Austria	female	4.040944	4.161906	4.288339
2011	Austria	female	4.087868	4.199689	4.322685
2012	Austria	female	4.132165	4.237815	4.357333
2013	Austria	female	4.184429	4.276999	4.389360
2014	Austria	female	4.234605	4.316763	4.429903
2015	Austria	female	4.275584	4.358605	4.480788
2016	Austria	female	4.310204	4.403287	4.532076
2017	Austria	female	4.345091	4.449014	4.585876
2018	Austria	female	4.376074	4.496176	4.640846
2019	Austria	female	4.407278	4.538810	4.696478
2020	Austria	female	4.435362	4.583822	4.752780
2021	Austria	female	4.463632	4.634616	4.809759
2022	Austria	female	4.499031	4.684298	4.867805
2017	Bulgaria	female	2.955254	3.118614	3.321842
2018	Bulgaria	female	2.994959	3.162940	3.339415
2019	Bulgaria	female	3.033511	3.212301	3.395708
2020	Bulgaria	female	3.045902	3.247493	3.457382
2021	Bulgaria	female	3.071607	3.303859	3.534979
2022	Bulgaria	female	3.064799	3.345219	3.629517
2004	Belgium	female	4.753337	4.928705	5.084123
2005	Belgium	female	4.768259	4.939547	5.088362
2006	Belgium	female	4.784249	4.949718	5.087760
2007	Belgium	female	4.799884	4.960388	5.090092
2008	Belgium	female	4.822057	4.968367	5.097161
2009	Belgium	female	4.844422	4.979019	5.112787
2010	Belgium	female	4.864963	4.989918	5.127725
2011	Belgium	female	4.885593	5.000024	5.138914
2012	Belgium	female	4.905554	5.011070	5.153849
2013	Belgium	female	4.910867	5.024671	5.169136
2014	Belgium	female	4.915651	5.041120	5.186393

(Continued on Next Page...)

Table S2: Estimate NHV by country and sex from 2004-2019 *(continued)*

year	country	sex	0.025quant	median	0.975quant
2015	Belgium	female	4.925226	5.050290	5.206600
2016	Belgium	female	4.931914	5.063828	5.226887
2017	Belgium	female	4.935126	5.073770	5.247254
2018	Belgium	female	4.938343	5.084815	5.267701
2019	Belgium	female	4.941566	5.101371	5.288228
2020	Belgium	female	4.944794	5.115536	5.308836
2021	Belgium	female	4.949297	5.128701	5.329524
2022	Belgium	female	4.954104	5.137231	5.349836
2017	Cyprus	female	2.446475	2.630950	2.813923
2018	Cyprus	female	2.470842	2.615918	2.770624
2019	Cyprus	female	2.459626	2.605609	2.777563
2020	Cyprus	female	2.399854	2.600710	2.790719
2021	Cyprus	female	2.336283	2.591249	2.799189
2022	Cyprus	female	2.274287	2.598293	2.863892
2006	Czechia	female	4.599881	4.777091	4.913460
2007	Czechia	female	4.574558	4.745225	4.870537
2008	Czechia	female	4.549155	4.712213	4.827989
2009	Czechia	female	4.523896	4.684113	4.787394
2010	Czechia	female	4.495609	4.653271	4.750305
2011	Czechia	female	4.471246	4.619495	4.718923
2012	Czechia	female	4.446398	4.588185	4.683594
2013	Czechia	female	4.421278	4.555365	4.651769
2014	Czechia	female	4.389729	4.524141	4.625032
2015	Czechia	female	4.359839	4.497901	4.597731
2016	Czechia	female	4.323843	4.467589	4.573183
2017	Czechia	female	4.286892	4.436518	4.549060
2018	Czechia	female	4.260820	4.404281	4.527169
2019	Czechia	female	4.234907	4.372992	4.509752
2020	Czechia	female	4.208398	4.342969	4.492409
2021	Czechia	female	4.170297	4.310345	4.475433
2022	Czechia	female	4.130555	4.280354	4.463742
2004	Switzerland	female	2.626681	2.739179	2.879000
2005	Switzerland	female	2.667778	2.771767	2.905889
2006	Switzerland	female	2.708207	2.805741	2.933115
2007	Switzerland	female	2.747922	2.841061	2.960691
2008	Switzerland	female	2.786662	2.873517	2.988528

(Continued on Next Page...)

Table S2: Estimate NHV by country and sex from 2004-2019 *(continued)*

year	country	sex	0.025quant	median	0.975quant
2009	Switzerland	female	2.827438	2.909365	3.016853
2010	Switzerland	female	2.860361	2.948323	3.048654
2011	Switzerland	female	2.895703	2.986844	3.080790
2012	Switzerland	female	2.933433	3.022768	3.114332
2013	Switzerland	female	2.965850	3.056185	3.147747
2014	Switzerland	female	2.997005	3.094638	3.180756
2015	Switzerland	female	3.026416	3.132675	3.226170
2016	Switzerland	female	3.053507	3.169798	3.278668
2017	Switzerland	female	3.081347	3.204209	3.321897
2018	Switzerland	female	3.110112	3.244129	3.375464
2019	Switzerland	female	3.139148	3.279264	3.431675
2020	Switzerland	female	3.168340	3.317385	3.491507
2021	Switzerland	female	3.195890	3.360054	3.552381
2022	Switzerland	female	3.224190	3.400590	3.614317
2004	Germany	female	4.608425	4.754839	4.916966
2005	Germany	female	4.599849	4.735299	4.886126
2006	Germany	female	4.586269	4.717227	4.857341
2007	Germany	female	4.572083	4.697857	4.833489
2008	Germany	female	4.557211	4.680821	4.809757
2009	Germany	female	4.545744	4.658635	4.783771
2010	Germany	female	4.530738	4.634310	4.758261
2011	Germany	female	4.513707	4.613086	4.734183
2012	Germany	female	4.490801	4.592418	4.712471
2013	Germany	female	4.467426	4.576897	4.693168
2014	Germany	female	4.444380	4.558130	4.676685
2015	Germany	female	4.422837	4.541738	4.668512
2016	Germany	female	4.404281	4.523478	4.654200
2017	Germany	female	4.382764	4.508930	4.638314
2018	Germany	female	4.358576	4.492731	4.629526
2019	Germany	female	4.327364	4.474504	4.616664
2020	Germany	female	4.295916	4.455082	4.603838
2021	Germany	female	4.264699	4.435746	4.591048
2022	Germany	female	4.237906	4.418943	4.578294
2004	Denmark	female	2.488565	2.605938	2.717544
2005	Denmark	female	2.526139	2.640767	2.740164
2006	Denmark	female	2.564281	2.671154	2.762975

(Continued on Next Page...)

Table S2: Estimate NHV by country and sex from 2004-2019 *(continued)*

year	country	sex	0.025quant	median	0.975quant
2007	Denmark	female	2.602998	2.704470	2.788135
2008	Denmark	female	2.642300	2.738037	2.818199
2009	Denmark	female	2.680643	2.774369	2.851143
2010	Denmark	female	2.720850	2.809468	2.882828
2011	Denmark	female	2.759447	2.845588	2.925323
2012	Denmark	female	2.801874	2.883952	2.965726
2013	Denmark	female	2.843085	2.918636	3.006261
2014	Denmark	female	2.881737	2.958353	3.044103
2015	Denmark	female	2.913538	2.991723	3.088167
2016	Denmark	female	2.945451	3.032236	3.134852
2017	Denmark	female	2.976872	3.072948	3.185511
2018	Denmark	female	3.009854	3.114324	3.237803
2019	Denmark	female	3.039793	3.149028	3.288694
2020	Denmark	female	3.064266	3.191208	3.337181
2021	Denmark	female	3.091046	3.231469	3.388680
2022	Denmark	female	3.121496	3.271005	3.441476
2010	Estonia	female	2.712585	2.807739	2.885302
2011	Estonia	female	2.740018	2.828649	2.903997
2012	Estonia	female	2.764124	2.849791	2.924152
2013	Estonia	female	2.783987	2.870728	2.943813
2014	Estonia	female	2.803679	2.893038	2.960213
2015	Estonia	female	2.829431	2.911736	2.977041
2016	Estonia	female	2.855434	2.934417	3.003339
2017	Estonia	female	2.872642	2.955193	3.026714
2018	Estonia	female	2.889775	2.977300	3.054309
2019	Estonia	female	2.911482	2.999718	3.082475
2020	Estonia	female	2.928030	3.022951	3.110941
2021	Estonia	female	2.941342	3.045296	3.139833
2022	Estonia	female	2.956208	3.069997	3.168887
2004	Spain	female	4.504645	4.679303	4.882818
2005	Spain	female	4.398208	4.548768	4.739438
2006	Spain	female	4.289840	4.423814	4.600748
2007	Spain	female	4.177624	4.299755	4.466166
2008	Spain	female	4.066658	4.180841	4.335046
2009	Spain	female	3.965286	4.062709	4.206594
2010	Spain	female	3.858072	3.952412	4.078485

(Continued on Next Page...)

Table S2: Estimate NHV by country and sex from 2004-2019 *(continued)*

year	country	sex	0.025quant	median	0.975quant
2011	Spain	female	3.748886	3.842315	3.958075
2012	Spain	female	3.642618	3.737187	3.843626
2013	Spain	female	3.545995	3.636059	3.730048
2014	Spain	female	3.441441	3.536817	3.621179
2015	Spain	female	3.344977	3.440848	3.516975
2016	Spain	female	3.251491	3.346616	3.420922
2017	Spain	female	3.156576	3.252368	3.328890
2018	Spain	female	3.063828	3.159841	3.241222
2019	Spain	female	2.975365	3.069551	3.157538
2020	Spain	female	2.889302	2.985033	3.076954
2021	Spain	female	2.805730	2.903955	2.998559
2022	Spain	female	2.723722	2.823784	2.922291
2004	France	female	4.860738	5.026449	5.154656
2005	France	female	4.780526	4.935088	5.053465
2006	France	female	4.703313	4.843147	4.954260
2007	France	female	4.621476	4.749313	4.854717
2008	France	female	4.534260	4.658169	4.757012
2009	France	female	4.443631	4.571115	4.668687
2010	France	female	4.352821	4.481255	4.579245
2011	France	female	4.263869	4.393754	4.492465
2012	France	female	4.185106	4.315402	4.412884
2013	France	female	4.108121	4.233075	4.337252
2014	France	female	4.032322	4.155058	4.256404
2015	France	female	3.953072	4.080264	4.177067
2016	France	female	3.874256	4.005954	4.104518
2017	France	female	3.797011	3.929962	4.034855
2018	France	female	3.721306	3.855256	3.968500
2019	France	female	3.647111	3.783043	3.904226
2020	France	female	3.574809	3.709246	3.840994
2021	France	female	3.502502	3.642894	3.778785
2022	France	female	3.431820	3.574585	3.717584
2017	Finland	female	2.031178	2.149249	2.250289
2018	Finland	female	2.058736	2.175331	2.270138
2019	Finland	female	2.073179	2.197434	2.338795
2020	Finland	female	2.062621	2.218542	2.405112
2021	Finland	female	2.045617	2.246777	2.472311

(Continued on Next Page...)

Table S2: Estimate NHV by country and sex from 2004-2019 *(continued)*

year	country	sex	0.025quant	median	0.975quant
2022	Finland	female	2.023181	2.272947	2.547662
2004	Greece	female	3.086101	3.226197	3.356151
2005	Greece	female	3.066892	3.196781	3.325205
2006	Greece	female	3.050109	3.169539	3.294889
2007	Greece	female	3.033393	3.142664	3.258280
2008	Greece	female	3.016713	3.115604	3.222211
2009	Greece	female	2.995061	3.091100	3.190692
2010	Greece	female	2.971392	3.066188	3.163412
2011	Greece	female	2.944319	3.041964	3.136675
2012	Greece	female	2.917457	3.014951	3.110175
2013	Greece	female	2.890841	2.988486	3.080325
2014	Greece	female	2.864467	2.960698	3.054306
2015	Greece	female	2.838334	2.930976	3.028508
2016	Greece	female	2.812440	2.905751	3.003714
2017	Greece	female	2.786782	2.879803	2.982835
2018	Greece	female	2.760716	2.854590	2.957939
2019	Greece	female	2.733438	2.829992	2.933250
2020	Greece	female	2.706431	2.810920	2.908768
2021	Greece	female	2.680167	2.785614	2.885156
2022	Greece	female	2.655134	2.763126	2.866030
2015	Croatia	female	3.662954	3.855509	4.056894
2016	Croatia	female	3.780372	3.953263	4.136959
2017	Croatia	female	3.904693	4.054573	4.226656
2018	Croatia	female	3.990915	4.163482	4.357730
2019	Croatia	female	4.079011	4.268547	4.511060
2020	Croatia	female	4.163259	4.399341	4.657319
2021	Croatia	female	4.231980	4.530046	4.826874
2022	Croatia	female	4.283629	4.642097	5.021880
2011	Hungary	female	4.349776	4.571719	4.764499
2012	Hungary	female	4.309988	4.513142	4.683895
2013	Hungary	female	4.271592	4.460993	4.614039
2014	Hungary	female	4.235215	4.411618	4.555548
2015	Hungary	female	4.199156	4.349337	4.494475
2016	Hungary	female	4.129226	4.305021	4.449953
2017	Hungary	female	4.052095	4.249679	4.403086
2018	Hungary	female	3.971077	4.187805	4.364077

(Continued on Next Page...)

Table S2: Estimate NHV by country and sex from 2004-2019 *(continued)*

year	country	sex	0.025quant	median	0.975quant
2019	Hungary	female	3.892660	4.132993	4.335398
2020	Hungary	female	3.818134	4.084492	4.311446
2021	Hungary	female	3.745035	4.039111	4.287633
2022	Hungary	female	3.673336	3.987933	4.263960
2004	Italy	female	5.003464	5.146865	5.354525
2005	Italy	female	4.969202	5.107559	5.301872
2006	Italy	female	4.935175	5.069477	5.249347
2007	Italy	female	4.901381	5.030455	5.192950
2008	Italy	female	4.867818	4.991574	5.137161
2009	Italy	female	4.831634	4.953935	5.083678
2010	Italy	female	4.793832	4.915164	5.038097
2011	Italy	female	4.756199	4.876081	4.995010
2012	Italy	female	4.717633	4.837252	4.952291
2013	Italy	female	4.678586	4.802915	4.909938
2014	Italy	female	4.639624	4.767496	4.867947
2015	Italy	female	4.595683	4.729644	4.826315
2016	Italy	female	4.555452	4.692541	4.789670
2017	Italy	female	4.515718	4.654662	4.765324
2018	Italy	female	4.476575	4.618528	4.740883
2019	Italy	female	4.436312	4.583231	4.714252
2020	Italy	female	4.395896	4.548069	4.687772
2021	Italy	female	4.353507	4.512817	4.661439
2022	Italy	female	4.311373	4.474869	4.635255
2017	Lithuania	female	2.567954	2.702133	2.874736
2018	Lithuania	female	2.711482	2.852865	3.012051
2019	Lithuania	female	2.841251	3.007971	3.182122
2020	Lithuania	female	2.969932	3.174886	3.403856
2021	Lithuania	female	3.099896	3.347179	3.643614
2022	Lithuania	female	3.199185	3.501790	3.914059
2013	Luxembourg	female	4.726477	4.949570	5.267130
2014	Luxembourg	female	4.814400	5.058309	5.355194
2015	Luxembourg	female	4.919486	5.158378	5.426783
2016	Luxembourg	female	5.007898	5.263633	5.548727
2017	Luxembourg	female	5.090465	5.368788	5.646570
2018	Luxembourg	female	5.158050	5.484543	5.805448
2019	Luxembourg	female	5.202798	5.601645	5.967219

(Continued on Next Page...)

Table S2: Estimate NHV by country and sex from 2004-2019 *(continued)*

year	country	sex	0.025quant	median	0.975quant
2020	Luxembourg	female	5.259403	5.713808	6.102131
2021	Luxembourg	female	5.316630	5.831470	6.244278
2022	Luxembourg	female	5.374484	5.957734	6.409344
2017	Latvia	female	2.535846	2.677892	2.811642
2018	Latvia	female	2.640800	2.792581	2.938614
2019	Latvia	female	2.749407	2.914481	3.056635
2020	Latvia	female	2.834098	3.028720	3.222079
2021	Latvia	female	2.913740	3.168969	3.415335
2022	Latvia	female	2.997064	3.310926	3.632609
2017	Malta	female	2.377570	2.555494	2.711631
2018	Malta	female	2.376073	2.539929	2.686867
2019	Malta	female	2.347676	2.524545	2.679804
2020	Malta	female	2.311834	2.513243	2.682229
2021	Malta	female	2.256573	2.493475	2.700241
2022	Malta	female	2.196017	2.479374	2.728162
2004	Netherlands	female	2.602690	2.705632	2.824526
2005	Netherlands	female	2.659001	2.759838	2.874629
2006	Netherlands	female	2.717502	2.819180	2.922157
2007	Netherlands	female	2.777291	2.874020	2.973891
2008	Netherlands	female	2.838394	2.933740	3.038758
2009	Netherlands	female	2.902079	2.988639	3.098946
2010	Netherlands	female	2.965532	3.049264	3.159039
2011	Netherlands	female	3.030461	3.110214	3.218458
2012	Netherlands	female	3.095581	3.176008	3.282548
2013	Netherlands	female	3.157581	3.241965	3.348358
2014	Netherlands	female	3.218416	3.311928	3.424295
2015	Netherlands	female	3.279749	3.379642	3.497853
2016	Netherlands	female	3.342252	3.444922	3.573988
2017	Netherlands	female	3.406840	3.514502	3.653512
2018	Netherlands	female	3.473827	3.588371	3.738175
2019	Netherlands	female	3.538273	3.659044	3.825366
2020	Netherlands	female	3.604024	3.733569	3.923212
2021	Netherlands	female	3.671078	3.807553	4.023717
2022	Netherlands	female	3.739123	3.881499	4.126797
2006	Poland	female	4.032279	4.232842	4.537913
2007	Poland	female	4.022716	4.209174	4.488761

(Continued on Next Page...)

Table S2: Estimate NHV by country and sex from 2004-2019 *(continued)*

year	country	sex	0.025quant	median	0.975quant
2008	Poland	female	4.013176	4.187799	4.442965
2009	Poland	female	4.001438	4.165724	4.397641
2010	Poland	female	3.986298	4.149503	4.352784
2011	Poland	female	3.979180	4.126305	4.307338
2012	Poland	female	3.974777	4.109124	4.264534
2013	Poland	female	3.963227	4.087104	4.235236
2014	Poland	female	3.950580	4.067836	4.205268
2015	Poland	female	3.937463	4.046506	4.170202
2016	Poland	female	3.918957	4.031999	4.138782
2017	Poland	female	3.894375	4.006397	4.120388
2018	Poland	female	3.866016	3.986087	4.105609
2019	Poland	female	3.834256	3.967192	4.084215
2020	Poland	female	3.802758	3.942779	4.074831
2021	Poland	female	3.769017	3.921824	4.067606
2022	Poland	female	3.736439	3.899084	4.062755
2011	Portugal	female	2.853600	2.993550	3.171013
2012	Portugal	female	2.848492	2.970889	3.143723
2013	Portugal	female	2.823703	2.937229	3.115895
2014	Portugal	female	2.791781	2.911360	3.076875
2015	Portugal	female	2.750132	2.896809	3.043829
2016	Portugal	female	2.714950	2.872076	3.026457
2017	Portugal	female	2.680219	2.846310	3.021533
2018	Portugal	female	2.632801	2.817884	3.028163
2019	Portugal	female	2.577436	2.794656	3.016033
2020	Portugal	female	2.523136	2.768821	3.003956
2021	Portugal	female	2.469982	2.746178	2.991932
2022	Portugal	female	2.418891	2.720391	2.979961
2017	Romania	female	2.486490	2.638569	2.798828
2018	Romania	female	2.631490	2.760667	2.921779
2019	Romania	female	2.763753	2.890966	3.056924
2020	Romania	female	2.884204	3.023422	3.190795
2021	Romania	female	2.981762	3.160975	3.411926
2022	Romania	female	3.078163	3.311118	3.627887
2004	Sweden	female	1.743347	1.822340	1.890626
2005	Sweden	female	1.790677	1.864647	1.931379
2006	Sweden	female	1.839293	1.907955	1.973010

(Continued on Next Page...)

Table S2: Estimate NHV by country and sex from 2004-2019 *(continued)*

year	country	sex	0.025quant	median	0.975quant
2007	Sweden	female	1.889229	1.953785	2.015539
2008	Sweden	female	1.940252	2.002405	2.060917
2009	Sweden	female	1.991951	2.053001	2.110539
2010	Sweden	female	2.045027	2.105433	2.159884
2011	Sweden	female	2.099472	2.158224	2.213027
2012	Sweden	female	2.153431	2.210306	2.268493
2013	Sweden	female	2.206032	2.266084	2.325078
2014	Sweden	female	2.260673	2.321541	2.383097
2015	Sweden	female	2.318576	2.378664	2.442661
2016	Sweden	female	2.372628	2.439669	2.508474
2017	Sweden	female	2.427096	2.497659	2.576503
2018	Sweden	female	2.482761	2.556905	2.646281
2019	Sweden	female	2.539709	2.618921	2.721636
2020	Sweden	female	2.594627	2.680676	2.799340
2021	Sweden	female	2.650392	2.744825	2.879263
2022	Sweden	female	2.707356	2.817257	2.961468
2011	Slovenia	female	2.638634	2.766283	2.851495
2012	Slovenia	female	2.676077	2.786193	2.865845
2013	Slovenia	female	2.711739	2.811347	2.880106
2014	Slovenia	female	2.740556	2.839933	2.905399
2015	Slovenia	female	2.776596	2.862361	2.934632
2016	Slovenia	female	2.802885	2.889001	2.963710
2017	Slovenia	female	2.838022	2.917714	2.996552
2018	Slovenia	female	2.864151	2.940017	3.035647
2019	Slovenia	female	2.883440	2.962796	3.078287
2020	Slovenia	female	2.899387	2.993771	3.115848
2021	Slovenia	female	2.908510	3.025173	3.156026
2022	Slovenia	female	2.917295	3.057086	3.199539
2017	Slovakia	female	3.352496	3.547030	3.760956
2018	Slovakia	female	3.545181	3.731166	3.944140
2019	Slovakia	female	3.698529	3.921240	4.131305
2020	Slovakia	female	3.838485	4.129527	4.428900
2021	Slovakia	female	3.984441	4.345077	4.734480
2022	Slovakia	female	4.135798	4.589135	5.085681

Table S3: Estimate NHV by epidemic period

country	sex	period	0.025quant	median	0.975quant
Austria	male	Epidemic	0.2961026	0.3247069	0.3652698
Bulgaria	male	Epidemic	0.1389198	0.1589565	0.1893942
Belgium	male	Epidemic	0.2676780	0.2938237	0.3168746
Cyprus	male	Epidemic	0.1381502	0.1759684	0.2235481
Czechia	male	Epidemic	0.1863108	0.2094735	0.2302330
Switzerland	male	Epidemic	0.2514801	0.2815730	0.3118547
Germany	male	Epidemic	0.4073919	0.4527449	0.4930440
Denmark	male	Epidemic	0.2845631	0.3158190	0.3570682
Estonia	male	Epidemic	0.0802252	0.0878454	0.0978270
Spain	male	Epidemic	0.1903019	0.2093903	0.2421676
France	male	Epidemic	0.4052236	0.4399576	0.4828990
Finland	male	Epidemic	0.3531941	0.4059161	0.4850489
Greece	male	Epidemic	0.1338503	0.1444834	0.1596465
Croatia	male	Epidemic	0.0618355	0.0713298	0.0836418
Hungary	male	Epidemic	0.0836844	0.0982155	0.1232349
Italy	male	Epidemic	0.0583614	0.0631818	0.0702774
Lithuania	male	Epidemic	0.0930986	0.1072762	0.1250641
Luxembourg	male	Epidemic	0.1078166	0.1251759	0.1456070
Latvia	male	Epidemic	0.1277719	0.1528351	0.1765361
Malta	male	Epidemic	0.1543045	0.1852309	0.2188238
Netherlands	male	Epidemic	0.1516117	0.1737363	0.2078641
Poland	male	Epidemic	0.1424516	0.1566970	0.1722637
Portugal	male	Epidemic	0.1830262	0.2182611	0.2640315
Romania	male	Epidemic	0.1614400	0.1928857	0.2182646
Sweden	male	Epidemic	0.3168408	0.3538661	0.3993035
Slovenia	male	Epidemic	0.1150790	0.1311057	0.1460913
Slovakia	male	Epidemic	0.0930273	0.1086417	0.1255407
Austria	male	Post-Epidemic	0.8530829	0.9099770	0.9743933
Bulgaria	male	Post-Epidemic	0.7823400	0.9177289	1.0831375
Belgium	male	Post-Epidemic	0.9876400	1.0568858	1.1170280
Cyprus	male	Post-Epidemic	1.1772485	1.3574490	1.5908075
Czechia	male	Post-Epidemic	1.0526479	1.1321710	1.2019796
Switzerland	male	Post-Epidemic	0.9279105	1.0115468	1.0885385
Germany	male	Post-Epidemic	1.0606909	1.1125397	1.1676724
Denmark	male	Post-Epidemic	0.8544293	0.9177864	0.9828771
Estonia	male	Post-Epidemic	1.0618199	1.1277465	1.2060713

(Continued on Next Page...)

Table S3: Estimate NHV by epidemic period *(continued)*

country	sex	period	0.025quant	median	0.975quant
Spain	male	Post-Epidemic	0.9280577	1.0082207	1.0901918
France	male	Post-Epidemic	1.0617575	1.1214084	1.1929081
Finland	male	Post-Epidemic	0.8313261	0.9560583	1.1258789
Greece	male	Post-Epidemic	0.9942394	1.0576204	1.1224754
Croatia	male	Post-Epidemic	0.8458377	0.9362992	1.0273226
Hungary	male	Post-Epidemic	0.7822745	0.8747332	0.9494905
Italy	male	Post-Epidemic	0.8603274	0.9059928	0.9544611
Lithuania	male	Post-Epidemic	0.8358249	0.9385477	1.0637289
Luxembourg	male	Post-Epidemic	0.7373418	0.8069946	0.8905483
Latvia	male	Post-Epidemic	0.7347193	0.8916349	1.0361230
Malta	male	Post-Epidemic	0.7677525	0.8893956	1.0293716
Netherlands	male	Post-Epidemic	0.8447200	0.9104174	0.9732034
Poland	male	Post-Epidemic	0.7950836	0.8511499	0.9138764
Portugal	male	Post-Epidemic	0.8181195	0.9463074	1.0935674
Romania	male	Post-Epidemic	0.7791793	0.8719217	1.0127820
Sweden	male	Post-Epidemic	0.9060374	0.9660835	1.0278839
Slovenia	male	Post-Epidemic	0.8254595	0.9041156	0.9735542
Slovakia	male	Post-Epidemic	0.5620056	0.6406490	0.7110576
Austria	female	Epidemic	0.2837441	0.3068262	0.3317178
Bulgaria	female	Epidemic	0.1291488	0.1500241	0.1718772
Belgium	female	Epidemic	0.2207433	0.2340601	0.2484315
Cyprus	female	Epidemic	0.0950042	0.1135314	0.1340445
Czechia	female	Epidemic	0.1671847	0.1791001	0.1917894
Switzerland	female	Epidemic	0.2034044	0.2244011	0.2410499
Germany	female	Epidemic	0.3927454	0.4196070	0.4479282
Denmark	female	Epidemic	0.2805334	0.3055506	0.3300202
Estonia	female	Epidemic	0.0712495	0.0782305	0.0842722
Spain	female	Epidemic	0.1682595	0.1819127	0.2007120
France	female	Epidemic	0.3525840	0.3874634	0.4147254
Finland	female	Epidemic	0.3581683	0.4055745	0.4508862
Greece	female	Epidemic	0.1057749	0.1136848	0.1224595
Croatia	female	Epidemic	0.0578211	0.0651453	0.0749464
Hungary	female	Epidemic	0.0766009	0.0888672	0.1025201
Italy	female	Epidemic	0.0470562	0.0511942	0.0551493
Lithuania	female	Epidemic	0.0929536	0.1048487	0.1191917
Luxembourg	female	Epidemic	0.0964758	0.1087169	0.1261391

(Continued on Next Page...)

Table S3: Estimate NHV by epidemic period *(continued)*

country	sex	period	0.025quant	median	0.975quant
Latvia	female	Epidemic	0.1065353	0.1249193	0.1418781
Malta	female	Epidemic	0.1479663	0.1649290	0.1891140
Netherlands	female	Epidemic	0.1403771	0.1586452	0.1900386
Poland	female	Epidemic	0.1270995	0.1359868	0.1483919
Portugal	female	Epidemic	0.1736436	0.1994242	0.2315088
Romania	female	Epidemic	0.1728846	0.1927035	0.2154959
Sweden	female	Epidemic	0.2800377	0.3115416	0.3483092
Slovenia	female	Epidemic	0.1117062	0.1205907	0.1305004
Slovakia	female	Epidemic	0.0989316	0.1143543	0.1343923
Austria	female	Post-Epidemic	0.8970601	0.9537846	0.9995732
Bulgaria	female	Post-Epidemic	0.8831858	0.9816891	1.0838686
Belgium	female	Post-Epidemic	1.0050206	1.0457638	1.0793023
Cyprus	female	Post-Epidemic	1.0161588	1.1447752	1.2968389
Czechia	female	Post-Epidemic	1.0380854	1.0911240	1.1511960
Switzerland	female	Post-Epidemic	0.9392716	0.9991395	1.0668715
Germany	female	Post-Epidemic	1.0386183	1.0915676	1.1482201
Denmark	female	Post-Epidemic	0.8576652	0.9226262	0.9829440
Estonia	female	Post-Epidemic	1.0423757	1.0938975	1.1456008
Spain	female	Post-Epidemic	0.9399712	1.0020520	1.0657079
France	female	Post-Epidemic	1.0603268	1.1067383	1.1602217
Finland	female	Post-Epidemic	0.8455450	0.9383145	1.0711127
Greece	female	Post-Epidemic	0.9760275	1.0199925	1.0700552
Croatia	female	Post-Epidemic	0.8539702	0.9280852	1.0061937
Hungary	female	Post-Epidemic	0.8440750	0.9161328	0.9977147
Italy	female	Post-Epidemic	0.8682464	0.9125841	0.9631327
Lithuania	female	Post-Epidemic	0.9462452	1.0370617	1.1307461
Luxembourg	female	Post-Epidemic	0.7767598	0.8491808	0.9368589
Latvia	female	Post-Epidemic	0.8257720	0.9113118	1.0012395
Malta	female	Post-Epidemic	0.8062984	0.8945664	1.0215910
Netherlands	female	Post-Epidemic	0.8102648	0.8620882	0.9175611
Poland	female	Post-Epidemic	0.7668290	0.8040323	0.8430228
Portugal	female	Post-Epidemic	0.8756009	0.9820132	1.0843554
Romania	female	Post-Epidemic	0.8100965	0.8870977	0.9617592
Sweden	female	Post-Epidemic	0.9243669	0.9827051	1.0419995
Slovenia	female	Post-Epidemic	0.8927724	0.9400193	0.9970225
Slovakia	female	Post-Epidemic	0.6406450	0.7149784	0.7858796

Table S4: Estimate relative change by age and epidemic period

age	sex	period	0.025quant	median	0.975quant
50	male	Pre-	0.6222053	0.6533698	0.6833842
51	male	Pre-	0.6416818	0.6656251	0.6879020
52	male	Pre-	0.6592677	0.6815937	0.6994560
53	male	Pre-	0.6776096	0.6970969	0.7142328
54	male	Pre-	0.6924641	0.7139882	0.7333720
55	male	Pre-	0.7089068	0.7311390	0.7527415
56	male	Pre-	0.7289271	0.7495422	0.7696026
57	male	Pre-	0.7505231	0.7690813	0.7868127
58	male	Pre-	0.7662270	0.7854083	0.8074882
59	male	Pre-	0.7804060	0.8007088	0.8222629
60	male	Pre-	0.7956348	0.8142463	0.8348948
61	male	Pre-	0.8042011	0.8257226	0.8456175
62	male	Pre-	0.8157176	0.8369881	0.8554958
63	male	Pre-	0.8301705	0.8472905	0.8687556
64	male	Pre-	0.8416070	0.8598079	0.8795001
65	male	Pre-	0.8542529	0.8732766	0.8938377
66	male	Pre-	0.8677460	0.8894433	0.9065529
67	male	Pre-	0.8849658	0.9048353	0.9252388
68	male	Pre-	0.9047495	0.9224522	0.9430781
69	male	Pre-	0.9158714	0.9405733	0.9618433
70	male	Pre-	0.9318820	0.9566880	0.9795191
71	male	Pre-	0.9485974	0.9737198	0.9954537
72	male	Pre-	0.9658392	0.9894204	1.0105642
73	male	Pre-	0.9835678	1.0058701	1.0296385
74	male	Pre-	0.9970748	1.0248482	1.0449809
75	male	Pre-	1.0137271	1.0409441	1.0617639
76	male	Pre-	1.0308115	1.0581002	1.0811283
77	male	Pre-	1.0453467	1.0746535	1.0995508
78	male	Pre-	1.0629160	1.0924531	1.1202138
79	male	Pre-	1.0785049	1.1101039	1.1348833
80	male	Pre-	1.0944649	1.1267834	1.1555908
81	male	Pre-	1.1049074	1.1420933	1.1727871
82	male	Pre-	1.1198229	1.1594414	1.1901931
83	male	Pre-	1.1361074	1.1732528	1.2098521
84	male	Pre-	1.1477130	1.1849660	1.2216739
85	male	Pre-	1.1579440	1.1976237	1.2324224

(Continued on Next Page...)

Table S4: Estimate relative change by age and epidemic period *(continued)*

age	sex	period	0.025quant	median	0.975quant
86	male	Pre-	1.1734826	1.2093617	1.2386285
87	male	Pre-	1.1816384	1.2175757	1.2472776
88	male	Pre-	1.1866461	1.2235984	1.2584300
89	male	Pre-	1.1899392	1.2303481	1.2616889
90	male	Pre-	1.1946845	1.2375402	1.2724510
91	male	Pre-	1.2013122	1.2416181	1.2810022
92	male	Pre-	1.2100312	1.2459908	1.2920233
93	male	Pre-	1.2128703	1.2542417	1.3035071
94	male	Pre-	1.2133847	1.2625152	1.3279619
95	male	Pre-	1.2099136	1.2688088	1.3506962
96	male	Pre-	1.1999127	1.2703347	1.3713414
97	male	Pre-	1.1931920	1.2741572	1.3981606
98	male	Pre-	1.1761062	1.2811552	1.4326137
99	male	Pre-	1.1560347	1.2911998	1.4580449
100	male	Pre-	1.1344307	1.3053740	1.4773485
50	male	Epi-	0.6883154	0.8104052	0.9898002
51	male	Epi-	0.7142334	0.8246640	0.9841284
52	male	Epi-	0.7357728	0.8389158	0.9748656
53	male	Epi-	0.7622906	0.8501604	0.9591878
54	male	Epi-	0.7896488	0.8654134	0.9486859
55	male	Epi-	0.8145691	0.8843014	0.9509256
56	male	Epi-	0.8380623	0.9020646	0.9620791
57	male	Epi-	0.8674671	0.9172548	0.9660522
58	male	Epi-	0.8892424	0.9325655	0.9830726
59	male	Epi-	0.9065305	0.9525965	1.0009867
60	male	Epi-	0.9242783	0.9694613	1.0160338
61	male	Epi-	0.9346854	0.9875483	1.0322758
62	male	Epi-	0.9463376	1.0051316	1.0510993
63	male	Epi-	0.9585794	1.0207241	1.0704292
64	male	Epi-	0.9753638	1.0369576	1.0930384
65	male	Epi-	0.9924421	1.0517322	1.1075837
66	male	Epi-	1.0116853	1.0665473	1.1312740
67	male	Epi-	1.0229519	1.0810994	1.1497987
68	male	Epi-	1.0336813	1.0919364	1.1619851
69	male	Epi-	1.0463344	1.1022848	1.1646383
70	male	Epi-	1.0569905	1.1099301	1.1764088

(Continued on Next Page...)

Table S4: Estimate relative change by age and epidemic period *(continued)*

age	sex	period	0.025quant	median	0.975quant
71	male	Epi-	1.0654733	1.1171033	1.1892558
72	male	Epi-	1.0717503	1.1248830	1.1998850
73	male	Epi-	1.0702287	1.1314607	1.2032970
74	male	Epi-	1.0762820	1.1352214	1.2055469
75	male	Epi-	1.0869140	1.1417025	1.2181176
76	male	Epi-	1.0951474	1.1472433	1.2177877
77	male	Epi-	1.0992321	1.1513562	1.2281963
78	male	Epi-	1.0971388	1.1518003	1.2294282
79	male	Epi-	1.0918210	1.1510440	1.2314422
80	male	Epi-	1.0884366	1.1517090	1.2267811
81	male	Epi-	1.0833947	1.1439691	1.2191653
82	male	Epi-	1.0752461	1.1365337	1.2194371
83	male	Epi-	1.0640121	1.1268748	1.2063660
84	male	Epi-	1.0550471	1.1144722	1.1827760
85	male	Epi-	1.0377403	1.0991675	1.1618227
86	male	Epi-	1.0266644	1.0825446	1.1346798
87	male	Epi-	1.0119757	1.0635615	1.1119161
88	male	Epi-	0.9989992	1.0495251	1.0996934
89	male	Epi-	0.9796118	1.0283914	1.0818339
90	male	Epi-	0.9489894	1.0066059	1.0648148
91	male	Epi-	0.9225675	0.9834939	1.0422294
92	male	Epi-	0.8895485	0.9597697	1.0192369
93	male	Epi-	0.8545814	0.9336864	1.0079216
94	male	Epi-	0.8211315	0.9108288	1.0021571
95	male	Epi-	0.7910191	0.8905596	0.9956785
96	male	Epi-	0.7566473	0.8662451	0.9879954
97	male	Epi-	0.7281744	0.8513442	0.9848695
98	male	Epi-	0.6910998	0.8299928	0.9813572
99	male	Epi-	0.6523472	0.8123359	0.9822552
100	male	Epi-	0.6160206	0.7910277	0.9797077
50	male	Post-	0.6707334	0.7630509	0.8367007
51	male	Post-	0.6926570	0.7641664	0.8256209
52	male	Post-	0.7057793	0.7695621	0.8164827
53	male	Post-	0.7246961	0.7726911	0.8187910
54	male	Post-	0.7400303	0.7794174	0.8226015
55	male	Post-	0.7527089	0.7877303	0.8212115

(Continued on Next Page...)

Table S4: Estimate relative change by age and epidemic period *(continued)*

age	sex	period	0.025quant	median	0.975quant
56	male	Post-	0.7694026	0.7966090	0.8244880
57	male	Post-	0.7762740	0.8064949	0.8333265
58	male	Post-	0.7841614	0.8159495	0.8442348
59	male	Post-	0.7931043	0.8252855	0.8546448
60	male	Post-	0.8041475	0.8341772	0.8653198
61	male	Post-	0.8102126	0.8433129	0.8752219
62	male	Post-	0.8171678	0.8530909	0.8846452
63	male	Post-	0.8276646	0.8613219	0.8936457
64	male	Post-	0.8373883	0.8705070	0.8988273
65	male	Post-	0.8499301	0.8793692	0.9089531
66	male	Post-	0.8622299	0.8898914	0.9213583
67	male	Post-	0.8787459	0.9044013	0.9364049
68	male	Post-	0.8931209	0.9201839	0.9511252
69	male	Post-	0.9089324	0.9390879	0.9734907
70	male	Post-	0.9212508	0.9589640	0.9963772
71	male	Post-	0.9394459	0.9791683	1.0155799
72	male	Post-	0.9634720	0.9973786	1.0322316
73	male	Post-	0.9851485	1.0162120	1.0503125
74	male	Post-	1.0047512	1.0353312	1.0714133
75	male	Post-	1.0186554	1.0564956	1.0842223
76	male	Post-	1.0339273	1.0701875	1.1015622
77	male	Post-	1.0505662	1.0865943	1.1212474
78	male	Post-	1.0677691	1.0995526	1.1319463
79	male	Post-	1.0778076	1.1108659	1.1399659
80	male	Post-	1.0849875	1.1174650	1.1527027
81	male	Post-	1.0932975	1.1258090	1.1652680
82	male	Post-	1.0918235	1.1332573	1.1713685
83	male	Post-	1.0937156	1.1379632	1.1747245
84	male	Post-	1.0889706	1.1433632	1.1839858
85	male	Post-	1.0898756	1.1481706	1.1814520
86	male	Post-	1.0951679	1.1482615	1.1906921
87	male	Post-	1.1032524	1.1513952	1.1993125
88	male	Post-	1.1056941	1.1532422	1.1967563
89	male	Post-	1.1183448	1.1553507	1.2033343
90	male	Post-	1.1204613	1.1612646	1.2077006
91	male	Post-	1.1163682	1.1679364	1.2144322

(Continued on Next Page...)

Table S4: Estimate relative change by age and epidemic period *(continued)*

age	sex	period	0.025quant	median	0.975quant
92	male	Post-	1.1233311	1.1712027	1.2264122
93	male	Post-	1.1238953	1.1775160	1.2325316
94	male	Post-	1.1190689	1.1833409	1.2571602
95	male	Post-	1.1073479	1.1950633	1.2925261
96	male	Post-	1.1065562	1.2082019	1.3304914
97	male	Post-	1.0981154	1.2135210	1.3617853
98	male	Post-	1.0982014	1.2198747	1.4066325
99	male	Post-	1.0856505	1.2299197	1.4652797
100	male	Post-	1.0695956	1.2502039	1.5261327
50	female	Pre-	0.7815025	0.8119882	0.8316218
51	female	Pre-	0.8071039	0.8261550	0.8452974
52	female	Pre-	0.8243696	0.8405848	0.8590363
53	female	Pre-	0.8383646	0.8547825	0.8725730
54	female	Pre-	0.8496527	0.8650251	0.8830974
55	female	Pre-	0.8573498	0.8727603	0.8910158
56	female	Pre-	0.8642901	0.8786580	0.8956651
57	female	Pre-	0.8702012	0.8843515	0.8988677
58	female	Pre-	0.8736729	0.8888036	0.9033350
59	female	Pre-	0.8778217	0.8933030	0.9095484
60	female	Pre-	0.8848391	0.8966094	0.9119570
61	female	Pre-	0.8872541	0.8988580	0.9156757
62	female	Pre-	0.8918710	0.9038785	0.9201624
63	female	Pre-	0.8967339	0.9117880	0.9263951
64	female	Pre-	0.9006645	0.9180494	0.9360093
65	female	Pre-	0.9115157	0.9284884	0.9450184
66	female	Pre-	0.9232702	0.9391268	0.9539645
67	female	Pre-	0.9343386	0.9493078	0.9658324
68	female	Pre-	0.9466225	0.9598666	0.9768599
69	female	Pre-	0.9599895	0.9725636	0.9910834
70	female	Pre-	0.9732785	0.9864411	1.0054248
71	female	Pre-	0.9839807	1.0007139	1.0193345
72	female	Pre-	0.9971176	1.0151275	1.0341489
73	female	Pre-	1.0113780	1.0297433	1.0475144
74	female	Pre-	1.0216369	1.0419215	1.0583797
75	female	Pre-	1.0338095	1.0503043	1.0690208
76	female	Pre-	1.0423978	1.0593416	1.0828863

(Continued on Next Page...)

Table S4: Estimate relative change by age and epidemic period *(continued)*

age	sex	period	0.025quant	median	0.975quant
77	female	Pre-	1.0550548	1.0721081	1.0931343
78	female	Pre-	1.0629836	1.0798352	1.1013940
79	female	Pre-	1.0701044	1.0872005	1.1107445
80	female	Pre-	1.0759576	1.0949800	1.1196235
81	female	Pre-	1.0809602	1.1015132	1.1283404
82	female	Pre-	1.0863399	1.1076949	1.1310186
83	female	Pre-	1.0887337	1.1100642	1.1292607
84	female	Pre-	1.0834601	1.1041591	1.1254115
85	female	Pre-	1.0750049	1.0992125	1.1225347
86	female	Pre-	1.0646421	1.0926805	1.1197021
87	female	Pre-	1.0678127	1.0850073	1.1139623
88	female	Pre-	1.0571061	1.0840884	1.1142019
89	female	Pre-	1.0552028	1.0846351	1.1160246
90	female	Pre-	1.0594275	1.0859167	1.1127814
91	female	Pre-	1.0614107	1.0890784	1.1149971
92	female	Pre-	1.0540312	1.0917476	1.1144254
93	female	Pre-	1.0496824	1.0903285	1.1205498
94	female	Pre-	1.0453982	1.0905359	1.1295095
95	female	Pre-	1.0389798	1.0900603	1.1392160
96	female	Pre-	1.0351422	1.0895820	1.1490104
97	female	Pre-	1.0054758	1.0883097	1.1553209
98	female	Pre-	0.9873885	1.0854842	1.1639615
99	female	Pre-	0.9540851	1.0856129	1.1827220
100	female	Pre-	0.9254002	1.0769370	1.2069627
50	female	Epi-	0.8706597	0.9865528	1.1377625
51	female	Epi-	0.9103717	1.0079176	1.1309209
52	female	Epi-	0.9374478	1.0193744	1.1285081
53	female	Epi-	0.9657908	1.0372702	1.1249016
54	female	Epi-	0.9968602	1.0535128	1.1181576
55	female	Epi-	1.0172019	1.0706959	1.1240805
56	female	Epi-	1.0422858	1.0882191	1.1361629
57	female	Epi-	1.0590987	1.1033540	1.1588060
58	female	Epi-	1.0696543	1.1158277	1.1677368
59	female	Epi-	1.0866250	1.1326183	1.1731917
60	female	Epi-	1.0950046	1.1436739	1.1897839
61	female	Epi-	1.1079754	1.1597323	1.2046173

(Continued on Next Page...)

Table S4: Estimate relative change by age and epidemic period *(continued)*

age	sex	period	0.025quant	median	0.975quant
62	female	Epi-	1.1217777	1.1693217	1.2140973
63	female	Epi-	1.1339007	1.1812069	1.2195257
64	female	Epi-	1.1517698	1.1968029	1.2374915
65	female	Epi-	1.1670144	1.2099839	1.2557815
66	female	Epi-	1.1774020	1.2214487	1.2667037
67	female	Epi-	1.1820983	1.2327550	1.2772745
68	female	Epi-	1.1937011	1.2408478	1.2839444
69	female	Epi-	1.1984540	1.2454778	1.2864408
70	female	Epi-	1.2025519	1.2459911	1.2935315
71	female	Epi-	1.1979456	1.2450143	1.2971380
72	female	Epi-	1.1981221	1.2481858	1.3038860
73	female	Epi-	1.1955629	1.2445500	1.2987913
74	female	Epi-	1.1908260	1.2418051	1.2986831
75	female	Epi-	1.1890762	1.2356508	1.2897444
76	female	Epi-	1.1807917	1.2289042	1.2845050
77	female	Epi-	1.1660568	1.2171169	1.2719802
78	female	Epi-	1.1573004	1.2054077	1.2609875
79	female	Epi-	1.1438565	1.1888438	1.2368196
80	female	Epi-	1.1229975	1.1696107	1.2140155
81	female	Epi-	1.0986725	1.1465074	1.1874915
82	female	Epi-	1.0609282	1.1213499	1.1581826
83	female	Epi-	1.0283878	1.0937087	1.1326144
84	female	Epi-	0.9994300	1.0614431	1.1033608
85	female	Epi-	0.9658781	1.0222269	1.0667208
86	female	Epi-	0.9340138	0.9867882	1.0338491
87	female	Epi-	0.8990711	0.9509264	0.9967888
88	female	Epi-	0.8623388	0.9121330	0.9560862
89	female	Epi-	0.8251271	0.8690286	0.9169674
90	female	Epi-	0.7876609	0.8311484	0.8718611
91	female	Epi-	0.7564707	0.7909154	0.8314868
92	female	Epi-	0.7217907	0.7537304	0.8009679
93	female	Epi-	0.6728842	0.7181364	0.7667129
94	female	Epi-	0.6358407	0.6826216	0.7438450
95	female	Epi-	0.5874116	0.6518856	0.7214812
96	female	Epi-	0.5443218	0.6184683	0.7014513
97	female	Epi-	0.5028856	0.5888582	0.6814435

(Continued on Next Page...)

Table S4: Estimate relative change by age and epidemic period *(continued)*

age	sex	period	0.025quant	median	0.975quant
98	female	Epi-	0.4638019	0.5588165	0.6674853
99	female	Epi-	0.4252971	0.5331682	0.6556862
100	female	Epi-	0.3914726	0.5131565	0.6466017
50	female	Post-	0.8561584	0.9196215	1.0056997
51	female	Post-	0.8696308	0.9157466	0.9794793
52	female	Post-	0.8768128	0.9169513	0.9599675
53	female	Post-	0.8837364	0.9179982	0.9619072
54	female	Post-	0.8900209	0.9170189	0.9605811
55	female	Post-	0.8933345	0.9191002	0.9528291
56	female	Post-	0.8999044	0.9243166	0.9545170
57	female	Post-	0.9056269	0.9267017	0.9537038
58	female	Post-	0.9067890	0.9301585	0.9574895
59	female	Post-	0.9099090	0.9325629	0.9603931
60	female	Post-	0.9103039	0.9340127	0.9650191
61	female	Post-	0.9055331	0.9313394	0.9597812
62	female	Post-	0.9014901	0.9257688	0.9584252
63	female	Post-	0.9007951	0.9246952	0.9600540
64	female	Post-	0.9065868	0.9287671	0.9600954
65	female	Post-	0.9144361	0.9357648	0.9633542
66	female	Post-	0.9240375	0.9425745	0.9707616
67	female	Post-	0.9330892	0.9524920	0.9788020
68	female	Post-	0.9449240	0.9649880	0.9896051
69	female	Post-	0.9564154	0.9773756	1.0043973
70	female	Post-	0.9696848	0.9891217	1.0194564
71	female	Post-	0.9771799	0.9984705	1.0288565
72	female	Post-	0.9883538	1.0094447	1.0396294
73	female	Post-	0.9941772	1.0164871	1.0465611
74	female	Post-	0.9975955	1.0214106	1.0508974
75	female	Post-	1.0046047	1.0268858	1.0513244
76	female	Post-	1.0054259	1.0302623	1.0585851
77	female	Post-	1.0054525	1.0355958	1.0642291
78	female	Post-	1.0086401	1.0388097	1.0640639
79	female	Post-	1.0140248	1.0417650	1.0653672
80	female	Post-	1.0181289	1.0462843	1.0674445
81	female	Post-	1.0208740	1.0492659	1.0715527
82	female	Post-	1.0234667	1.0492613	1.0751581

(Continued on Next Page...)

Table S4: Estimate relative change by age and epidemic period *(continued)*

age	sex	period	0.025quant	median	0.975quant
83	female	Post-	1.0279543	1.0518600	1.0793775
84	female	Post-	1.0277758	1.0494467	1.0796764
85	female	Post-	1.0202654	1.0496329	1.0780220
86	female	Post-	1.0168089	1.0478910	1.0753413
87	female	Post-	1.0110457	1.0421603	1.0756095
88	female	Post-	1.0045175	1.0395665	1.0735003
89	female	Post-	1.0019788	1.0377520	1.0804643
90	female	Post-	0.9963083	1.0387614	1.0845054
91	female	Post-	0.9978090	1.0405899	1.0900797
92	female	Post-	1.0031960	1.0469077	1.1002063
93	female	Post-	1.0104450	1.0569612	1.1098110
94	female	Post-	1.0183289	1.0652083	1.1371837
95	female	Post-	1.0122996	1.0725546	1.1579867
96	female	Post-	1.0089082	1.0780600	1.1748477
97	female	Post-	0.9980404	1.0853256	1.1877694
98	female	Post-	0.9885380	1.0855871	1.2118314
99	female	Post-	0.9626645	1.0915711	1.2313302
100	female	Post-	0.9308025	1.0983964	1.2661772

Table S5: Estimate relative change by diseases and epidemic period

disease	sex	period	0.025quant	median	0.975quant
Heart attack	male	Pre-	1.4587876	1.4813909	1.4988766
Heart attack	male	Epi-	1.1348368	1.1406969	1.1451895
Heart attack	male	Post-	1.2910142	1.3045119	1.3149078
Hypertension	male	Pre-	1.3289685	1.3441546	1.3604443
Hypertension	male	Epi-	1.1667703	1.1739821	1.1816768
Hypertension	male	Post-	1.2754537	1.2879117	1.3012526
High cholesterol	male	Pre-	1.0890480	1.1023475	1.1150636
High cholesterol	male	Epi-	1.0406806	1.0466022	1.0522285
High cholesterol	male	Post-	1.0723555	1.0830681	1.0932890
Stroke	male	Pre-	1.3269659	1.3482710	1.3739982
Stroke	male	Epi-	1.0055052	1.0058160	1.0061850
Stroke	male	Post-	1.2872210	1.3056506	1.3278639
Diabetes	male	Pre-	1.4113148	1.4311858	1.4567106

(Continued on Next Page...)

Table S5: Estimate relative change by diseases and epidemic period *(continued)*

disease	sex	period	0.025quant	median	0.975quant
Diabetes	male	Epi-	1.1310851	1.1367534	1.1439606
Diabetes	male	Post-	1.2930419	1.3065984	1.3239420
Chronic lung disease	male	Pre-	1.3853012	1.4160244	1.4441781
Chronic lung disease	male	Epi-	1.0221289	1.0236357	1.0249900
Chronic lung disease	male	Post-	1.2716534	1.2923890	1.3112867
Cancer	male	Pre-	1.7504840	1.7790278	1.8104277
Cancer	male	Epi-	1.3190351	1.3296289	1.3411839
Cancer	male	Post-	1.8702604	1.9043950	1.9420201
Stomach, duodenal, peptic ulcer	male	Pre-	1.1589364	1.1860163	1.2118429
Stomach, duodenal, peptic ulcer	male	Epi-	1.0923415	1.1075541	1.1219333
Stomach, duodenal, peptic ulcer	male	Post-	1.2366789	1.2785079	1.3187946
Parkinson	male	Pre-	1.0159426	1.0774327	1.1256920
Parkinson	male	Epi-	1.0145814	1.0706431	1.1144515
Parkinson	male	Post-	1.0144588	1.0700334	1.1134441
Cataracts	male	Pre-	0.9906488	1.0264563	1.0780816
Cataracts	male	Epi-	0.9992595	1.0020610	1.0059455
Cataracts	male	Post-	0.9830489	1.0486636	1.1466133
Hip, femoral fracture	male	Pre-	1.2151848	1.2541101	1.3073349
Hip, femoral fracture	male	Epi-	1.0418899	1.0488299	1.0580485
Hip, femoral fracture	male	Post-	1.2825910	1.3352866	1.4080768
Heart attack	female	Pre-	1.3225599	1.3400570	1.3579099
Heart attack	female	Epi-	1.0176509	1.0184883	1.0193323
Heart attack	female	Post-	1.2811672	1.2961777	1.3114703
Hypertension	female	Pre-	1.2846734	1.2944496	1.3073456
Hypertension	female	Epi-	1.0798183	1.0823307	1.0856248
Hypertension	female	Post-	1.2288441	1.2365316	1.2466568
High cholesterol	female	Pre-	1.1060872	1.1186127	1.1286852
High cholesterol	female	Epi-	1.1312700	1.1469607	1.1596071
High cholesterol	female	Post-	1.0857977	1.0958253	1.1038743
Stroke	female	Pre-	1.2646175	1.2953448	1.3176041
Stroke	female	Epi-	1.0388625	1.0429208	1.0458105
Stroke	female	Post-	1.1868877	1.2078659	1.2229787
Diabetes	female	Pre-	1.3230686	1.3420185	1.3622144
Diabetes	female	Epi-	1.1231901	1.1298381	1.1368629
Diabetes	female	Post-	1.2203246	1.2327305	1.2458965
Chronic lung disease	female	Pre-	1.2968971	1.3176336	1.3386418

(Continued on Next Page...)

Table S5: Estimate relative change by diseases and epidemic period *(continued)*

disease	sex	period	0.025quant	median	0.975quant
Chronic lung disease	female	Epi-	1.0728648	1.0774790	1.0820998
Chronic lung disease	female	Post-	1.2506895	1.2678775	1.2852522
Cancer	female	Pre-	1.5881518	1.6170753	1.6384253
Cancer	female	Epi-	1.1328284	1.1383544	1.1423873
Cancer	female	Post-	1.6654166	1.6988930	1.7236435
Stomach, duodenal, peptic ulcer	female	Pre-	1.1814648	1.2064351	1.2258661
Stomach, duodenal, peptic ulcer	female	Epi-	1.0229706	1.0258887	1.0281235
Stomach, duodenal, peptic ulcer	female	Post-	1.1947126	1.2216702	1.2426735
Parkinson	female	Pre-	0.5195846	0.6686785	0.8667815
Parkinson	female	Epi-	0.6524818	0.7691662	0.9109753
Parkinson	female	Post-	0.4636418	0.6234533	0.8454892
Cataracts	female	Pre-	1.2825368	1.6745456	2.1614218
Cataracts	female	Epi-	1.1208436	1.2666501	1.4238740
Cataracts	female	Post-	1.3211215	1.7805792	2.3692324
Hip, femoral fracture	female	Pre-	1.1725855	1.1984807	1.2371155
Hip, femoral fracture	female	Epi-	1.0211668	1.0241057	1.0283894
Hip, femoral fracture	female	Post-	1.1548769	1.1779192	1.2122096